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Abstract
With the ever-increasing varieties of sequencing techniques, the volume and scope of
genomic data are explosively expanded, offering unparalleled opportunities for researchers to
study gene-disease associations, identify biomarkers, and thus develop more effective diagnostic
and therapeutic strategies. In this project, I have developed a computational workflow and a new
scoring scheme, which combine statistical frequency-based analyses with two well-established
functional effect prediction tools FATHMM and PROVEAN, to evaluate nonsynonymous GSVs
and identify potential cancer-related protein-coding genes for downstream enrichment and proteinprotein interaction (PPI) studies.
This method has been applied to process a collection of 503 whole exome sequencing
datasets for patients with prostate cancer (PrCa). The datasets were downloaded from The Cancer
Genome Atlas as variant call format (VCF) files containing GSV information for paired tumor and
normal samples. Exploratory statistics revealed unusually high level of transitions G→A and C→T
among cancer samples. Furthermore, 5 GSVs were found significantly associated with the disease.
Among 61 high-scoring genes identified by our scoring scheme, 27 were found by PPI analysis to
have degrees of connection ≥ 4 with well-known PrCa-related genes. While 18 of them are
reportedly associated with PrCa, 9 genes (TRRAP, EPHB1, HERC2, MCM3, SPTA1, SALL1,
HERC1, TTN, and MYH6) have not been previously documented in relation to PrCa. Their
potential roles in PrCa could be investigated by further bioinformatics and wet-lab studies.
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Chapter 1: Introduction
Next-generation sequencing (NGS) technologies have become indispensable tools for
characterizing genomics, transcriptomics and proteomics. As of the beginning of the 21st century,
more and more biotechnology companies started to release various DNA sequencing platforms
and enormous amounts of data have been generated. At the same time, numerous computational
tools and analytical algorithms designed for handling large-scale sequencing data are emerging,
which greatly speeded up the research in many fields of biological sciences. In 2016, our research
group initiated the implementation of a bioinformatics pipeline named OncoMiner to integrate the
analysis of genetic sequence variants (GSVs). Over the past few years, more functional modules
have been added to the pipeline in order to generalize and expand the functionalities of OncoMiner
with the ultimate goal of establishing a reliable and versatile computational tool for mining NGS
data, identify cancer-related genetic sequence variants, and predict their functional effects in order
to help reveal potentially deleterious or pathogenic GSVs in various cancer types.
1.1 BACKGROUND AND SIGNIFICANCE
Cancer is a complex disease resulting from the accumulation of genetic alterations in the
human genome [1]. Although most alterations are considered as passengers and can be present in
normal cells, specific patterns of mutations may lead to tumor progressions [2]. Therefore,
discovering cancer-related genes and genetic sequence variants (GSVs) would contribute to the
establishment of promising tumor biomarkers or targeted therapies, which will improve the tumor
detection, prognosis and treatment [3]. In recent years, the rapid revolution in sequencing
techniques and increased molecular characterization of tumor tissues have accelerated the
development of cancer biomarkers [4].
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High-throughput sequencing technologies are yielding extensively large-scale sequencing
data. Analyzing these data could help identify genetic alterations in human genome, reveal
underlying biological processes and molecular mechanisms that promote cancer development [5].
Numerous bioinformatics and computational tools have been developed to annotate, predict and
interpret functional effects of variants. MutsigCV [6] analyzes frequent DNA mutations by
building a model assessing the background mutation processes. Polyphen-2 and SIFT are wellestablished software using naïve Bayes classifier and sequence homology-based method
respectively [7,8]. FATHMM creates alignment profile with hidden Markov model and predicts
variant impact based on evolutionary features [9]. PROVEAN predicts effect of variations at
protein level by calculating the difference between alignment scores after and before the
introduction of variants [10]. Other existing function prediction tools include MutationTaster,
Mutation Accessor etc. [11,12]. While these programs differ in their underlying algorithmic
approaches, most of them classify variants based on information of evolutionary conservation,
sequence homology or physicochemical properties of amino acids [13]. In addition, most of these
tools were developed before the most recent human genome build (GRCh38) was available and
remained not updated, which often limit their generalizability and applications.
Prostate cancer (PrCa) is the most frequently diagnosed cancer in men in over half of the
countries in the world. In 2020, an estimation of almost 1.4 million new cases and 375,000 deaths
worldwide made it the second most frequent cancer and the fifth leading cause of cancer deaths
among men [14]. Prostate-specific antigen test is commonly used for screening PrCa. However,
this procedure is painful and often leads to overtreatment [15]. Some blood-based and urine-based
biomarkers for PrCa like PCA3 and PTEN have been reported, but their clinical value remain
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undetermined [16]. Moreover, given the large set of GSVs or mutated genes, it is time-consuming
and expensive to identify the ones associated with PrCa.
1.2 ONCOMINER PIPELINE
A number of online or standalone tools have been developed to analyze NGS data, but few
of them can perform the whole NGS workflow. OncoMiner [17] is a bioinformatics pipeline
developed at UTEP initially for mining a local set of whole exome sequencing (WES) data. The
pipeline was implemented in 2016 as a web server (OncoMiner.utep.edu) to assist biomedical
researchers in our Border Biomedical Research Center at UTEP to analyze the datasets obtained
from the local population and cell lines. The pipeline is able to identify GSVs, link them with
associated research literature, visualize their genomic locations, and compare their occurrence
frequencies among different groups of subjects.
The OncoMiner homepage is shown in Figure 1.1. The input data format is limited to a
CSV file with specified columns including chromosome, position of GSV, reference base, altered
bases, quality score, gene name, genomic region, change type of amino acid (AA), etc. as shown
in Figure 1.2. On the submission page, an email address is preferred so that upon completion of
processing, users can be notified by an email containing a link to the annotated output file.

Figure 1.1: OncoMiner pipeline internal webpage

3

Figure 1.2: Example of OncoMiner input file
More recently, OncoMiner has been generalized to accept more common NGS files in
FastQ or BAM/SAM format. The codes for preprocessing FastQ and BAM/SAM files in parallel
environments have already been developed by other members in our group and published in 2018
[18]. As part of my work, I further extended the OncoMiner preprocessing (OP) program by
developing the functionality to preprocess variant call format (VCF) files (see Figure 1.3 for an
example).

Figure 1.3: VCF file example

1.3 RESEARCH AIMS
The purpose of my research is two-fold. First, we need to establish additional OncoMiner
modules for processing and analyzing NGS data in common file formats. Second, we want to
develop a computational workflow to identify potential cancer-associated GSVs and genes based
on a combination of comparative analyses of mutation frequencies between normal and tumor
samples, functional effect predictions, and protein-protein interaction networks. To achieve these
4

goals, I am using a large collection of VCF files containing WES data from about 500 prostate
cancer patients. The specific aims are:
1. Develop python scripts to efficiently convert VCF files to OncoMiner input files and evaluate
the performance of the script.
2. Compile GSVs in all VCF files and analyze the overall mutational landscape.
3. Predict functional effects of nonsynonymous GSVs in each protein-coding gene and design a
scoring scheme to assess the combined pathogenic effects of the GSVs on the gene.
4. Perform bioinformatics analysis on high-scoring genes selected in aim 3 above in order to
reveal their potential involvement in PrCa.
The proposed approach will efficiently process genomic data and reduce the large list of
variants and genes by prioritizing candidates that are more likely to be associated with PrCa. These
highly prioritized GSVs and genes will be reported so that they can be further investigated by wetlab studies. The overall workflow is being incorporated into the OncoMiner Pipeline to enable its
application in other types of cancer data.
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Chapter 2 Literature Review
In this chapter, I will provide background knowledge about the biology of Prostate Cancer
(PrCa), whole genome sequence (WGS) techniques, the developed software tools for WGS
analysis, and related computational techniques and statistical tools. At the end, I will also review
published articles about discoveries of PrCa-related genes, proteins or established biomarkers, etc.
Additional materials of DNA sequencing, popular programs for WGS analysis and PrCa genomics
can also be found in basic textbooks or published literatures.
2.1 PROSTATE CANCER
PrCa is one of the most common cancers and is among the leading causes of cancer-related
mortality in men. It alone accounts for more than 1 in 5 newly diagnosed cancer patients in 2020
[19]. It occurs in the prostate, a gland in men that produces the seminal fluid that nourishes and
transports sperm. The detection, because of the lack of obvious symptoms, is usually based on the
abnormal prostate-specific antigen (PSA) level in blood, followed by transrectal ultrasound guided
biopsy. However, PSA levels cannot typically reflect advanced stages of diseases [20]. Risk factors
for PrCa includes age, race, family history, eating habits et al. Age is closely related to the risk of
PrCa. It is rare among men younger than 40 years of age but the incidence rate begins to rise after
55 years of age and reach the peak at around 70 [21].
Earlier studies on the molecular basis for PrCa disparity have focused on the influence of
heritable mutations and single-nucleotide polymorphisms (SNPs). Most PrCa susceptibility alleles
identified based on genome-wide association studies (GWAS) were common, low-penetrance
variants [22]. Since 2007, many PrCa risk-associated SNPs have been identified through genomewide association studies (GWAS). Till 2018, more than 163 SNPs have been confirmed to be
associated with the risk of PrCa [23]. The effect of a single variant is usually modest, so many
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studies focus on the cumulative risk of a number of genetic variants. Zheng et al evaluated 16
SNPs from five chromosomal regions (three at 8q24 and one each at 17q12 and 17q24.3) in a
Swedish population. They assessed the individual and combined association of the SNPs with
PrCa. Five SNPs were found to be weakly associated with PrCa, but their combined effect was
much stronger [24]. Apart from these five variants, Helfand et al. also identified 4 additional
variants located on chromosomes 2p15, 10q11, 11q13 and Xp11[25]. They assessed both the
independent and cumulative risk of all 9 variants and found that PrCa cases had an increased
incidence of all 9 risk variants compared to controls or the previous 5 SNPs. Particularly, they
found that men with 6 or more variants were at greater than 6-fold increased risk for PrCa.
More recently, advances and general applications of high throughput sequencing
technologies have enabled researchers to identify the differences in genome between individuals.
Genomic studies enabled by next-generation sequencing (NGS) have focused on the identification
of somatic mutations. These variants between normal people and PrCa patients might be the cause
of disease. Xu et al sequenced 5 prostate cancer tissues and discovered, in 92 genes, 116
significantly disruptive mutations including frameshift insertions and deletions (indels) and
nonsynonymous mutations [26]. Chang et al examined 11,119 human tumors, spanning 41 cancer
types and detected a list of likely pathogenic mutations in well-known cancer genes including
SPOP, TP53 for PrCa [27]. The identification of more and more variants could provide a better
understanding of PrCa tumorgenesis and also help with the prediction of incidence and prognosis.
On-going discoveries of somatic mutations and their clustering on genes keep revealing classic
and novel PrCa-related genes like SPOP, FOXA1, PTEN, KCNT2 etc. and their roles in the
development of PrCa [28, 29]. A detailed review of PrCa driver genes and pathways is covered in
section 2.4.
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2.2 WHOLE GENOME SEQUENCING ANALYSIS
Human genome contains around 3 billion base pairs. The order of nucleotides in cells
contain the information and instructions for producing proteins and other molecules that is
essential for cells to carry out its daily work. Thus, knowledge of DNA sequences plays a key role
in understanding the biology of various diseases, reveal the mechanisms of their progression sand
developing targeted medication. However, pioneering DNA sequencing methods are very time
consuming and costly. Since the 21st century, with the advent and rapid development of DNA
sequencing technologies, a large amount of sequencing data has been generated more efficiently
and with low cost which revolutionized genomic and genetic researches.
There are currently numerous commercial platforms from different companies for NGS.
Illumina occupies the largest market share in the field. Its sequencers are able to generate 3 - 13
billion reads in a single run. Other companies including Pacific Biosciences, BGI Genomics,
Thermo Fisher Scientific, etc. are also developing efficient platforms with improved throughput,
read length and accuracy.
Exome is part of transcribed genome sequence that remains in the mature RNA. It only
constitutes less than 2% of the human whole genome, but about 85% of known disease-related
mutations were found within this region and mutations on exons were shown to cause the majority
of monogenic diseases [30]. Therefore, whole exome sequencing (WES) makes it more efficient
and cost-effective to identify associations between GSVs and diseases, which may lead to better
clinical diagnosis and treatments. Also, the low load of sequencing also reduces the complexity of
data processing, analysis and interpretation. In this section, I will describe classic procedures for
analyzing WGS and/or WES data from these platforms.
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In general, raw sequencing data directly from sequencers are stored in fastq format. Other
types of files used include standard flowgram format (SFF), binary alignment map (BAM) and so
on. Fastq is a text-based file using four lines for each sequence. It starts with a '@' character
followed by a sequence identifier. The basic structure is the same as Fasta file, but fastq contains
one more line specifying the quality score of data. Since the data is unaligned raw data, the preprocessing steps start with quality control (QC), and followed by alignment and post processing,
like removal of low coverage and duplicate reads [31].
2.2.1 Quality control
NGS data are being generated at an unprecedented pace, but the quality of data and
accuracy of analyses could be affected by artifacts from library or sequencing error [32]. Thus, the
first step after completing the sequencing run is to assess the quality of raw data and filter out reads
that do not meet pre-defined criterions. The early detection of low-quality data may reduce the
amount of further downstream analyses and increase accuracy. The quality of sequences is
generally measured by a Phred score 𝑄𝑃ℎ𝑟𝑒𝑑 = −10 log10 𝑃𝑒 , where Pe is the estimated
probability of error [33]. The scores generally range from 2 to 40 with higher scores corresponding
to higher quality in the call. A common practice is to filter out bases with Phred scores below 20,
but individuals may set other threshold based on their preferences or research demand. The fastq
file already incorporates the quality score. There are also several tools developed to assess the
quality of raw data from NGS. Removal of undesired sequences such as adaptors and trimming
low quality ends from reads and removal of contamination reads are also important as the
alignment of contaminating sequences to a reference genome will result in low alignment quality
[33].
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2.2.2 Read alignment
After removing undesired sequences and controlling for qualities, the following step is to
align reads to a reference genome. Currently, two commonly used sources for the human reference
genome assembly are hg38 from University of Santa Cruz (UCSC) and GRCh38 from Genome
Reference Consortium (GRC). The difference between two assemblies is tiny the same, but differ
in their nomenclature [34]. The mapping of sequenced reads to reference is a classical string match,
but due to the sheer amount of NGS data and huge volume of human genome, this process usually
involves complicated and computationally intensive work. Alignment results are usually stored in
a Sequence Alignment Map (SAM) or its equivalent compressed binary form BAM.
The aligned sequence still need to be processed as some bad features of sequences only
show up after alignment, The PCR amplification, which is conducted before alignment to ensure
good coverage and depth, may introduce duplicate reads to sequence data, which can affect further
downstream analyses [11]. Thus, it is necessary to remove them before the identification of
variants. Indels are most likely to be misinterpreted by variant calling algorithms as overlapping
reads may have different alignment results in indel regions. So, local realignment of indels using
known genetic variants as references are also important for improving accuracy [35,36]. Then base
quality score recalibration that recalculate the Phred score needs to be performed to correct for
error covariates and reduce false positives [37].
2.2.3 Variant calling
Variant calling is the identification of where aligned reads differ from a reference genome
and writing to a Variant Call Format (VCF) file, which is a widely used format for storing variant
information. Genetic variants take many forms and according to spectrum of sizes, they can be
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broadly classified into three categories: single nucleotide variant (SNV), indel and large structural
variant (SV) [38].
SNV is a substitution of one nucleotide by another. Based on the type of nucleotide, it
could be further divided into transition (interchange of the purine (Adenine/Guanine) or
pyrimidine (Cytosine/Thymine) nucleic acids and transversion (interchange between purine and
pyrimidine). Based on the effect of variations, it can be divided into missense (result in a change
at amino acid level), nonsense (result in a stop codon that shorten the protein sequence) and silent
(no change of amino acid). Short indels refers to a small piece of DNA, usually ranging from 1 to
tens of bases that has either been inserted into or deleted from the genome. They are the second
most abundant form of human genetic variations [39]. SV typically occurs over a large sequence.
This category usually includes copy number variant (CNV), translocation, inversion etc. in the
genome that may change the structure of coded proteins. CNV is the duplication or triplication of
a stretch of DNA. Inversion is the flip of some region along the genome. Translocation is the
exchange of sequences between two non-homologous chromosomes [40]. Long indels are also
considered as SVs.
According to the location of mutations, it can also be divided as germline mutations and
somatic mutations. Germline mutations occur in gametes. It can be incorporated into the DNA of
every cell and passed onto offspring. However, a somatic mutation only occurs in a single body
cell and cannot be inherited. It only affects tissues derived from the mutated cell.
Variants are identified by comparing mapped reads to the reference genome. There are
numerous variants calling programs that use different algorithms to decrease computational
complexity and increase accuracy. Techniques used in these algorithms will be covered in section
2.3. The results of variant calling are stored in a VCF file, which is composed of meta-information
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lines, a header line, and data lines. Meta-information lines describe the basic information and data
structure of the file. The header line names 8 required fields and may include other optional
columns. Each line in data section represents a variant, containing all information listed in the
header line.
2.2.4 Annotation
Variant annotation is an important but complex step in the analysis of NGS data. There are
many different types of information that could be associated with variants, from measures of
sequence conservation to predictions about the effect of a variant on protein structure and function
[41]. Many annotation tools have been developed. However, not as convenient as other steps that
have been automated, some part of annotation still requires manually review, interpretation, and
validation due to the inconsistence between various databases [42]. The most fundamental
annotation is categorizing variants based on their genomic regions (transcript, exon, intron, etc.).
Information regarding their gene symbol, amino acid change, allele frequency, possible
involvement in disease development, clinical significance, predicted functional effects are also
attached [43]. Most tools focus on the annotation of SNVs and indels in protein-coding region
using information from publicly available database, like dbSNP [44], OncoKB [45], COSMIC
[46], ClinVar etc.[47]. Knowledge added to variants will help researchers get a better
understanding of variants and their associations with diseases and thus select potentially
deleterious ones.
2.2.5 Visualization
The text-based mutation data are not always easy to read and summarize. Transforming
such information into a picture would help make sense of distribution features of data and
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understand the structure of our data. For example, a bar plot showing the type and abundance of
variants, a heatmap comparing variants in different groups or visualizing hotspot mutations [48].
2.2.6 Functional effect prediction
The large-scale variants identified from NGS data create challenges for researchers to look
at the pathogenic ones they are interested in as obtaining experimental evidence of pathogenicity
of these mutations could be disastrous. Speedy bioinformatics and computational tools have been
developed to predict functional effects of variants. These tools (covered in section 2.3) integrate
knowledge of amino acid structure, chemical properties, evolutionary conservation etc. to evaluate
the pathogenicity of mutations using machine learning or statistical methods [49]. These
predictions provide an effective alternative over experimental approaches to prioritize variants of
interest and to facilitate the understanding of the mechanisms and associations with disease or
pathological phenotypes underlying causal variants [50].
2.2.7 Prioritization and filtration
Selecting variants of interest from a list of thousands to millions of inconsequential variants
remains an analytical bottleneck. Filtration for this large candidate list could help prioritize casual
variants from common polymorphisms, which may accelerate and simplify variant interpretation.
In general, filtration and prioritization include three steps [51]. The first step is removal of less
reliable variant or artifacts produced during alignment and variant calling, which includes variants
with low quality, strand biased, located in SNV clusters, and/or supported by low-confidence read
alignment. The second step is to restrict variants to those of relatively low population frequency,
since a huge proportion of human diseases are caused by rare mutations [52]. The third step is to
prioritize the variants related to the disease according to their predicted coding-effects. The last
step is the most important one as the database-related annotation is limited to known disease and

13

variants but most variants could remain unknown. Predicted results could help researcher select
possibly deleterious variants for further analysis.
2.3 AVAILABLE SOFTWARE AND PROGRAMS
For each step in the analytic flow, plenty of bioinformatics and computational programs
have been well established and applied. The underlying algorithms of these tools are different and
some comprehensive reviews give detailed comparisons and evaluations of these tools [13, 17, 34,
53]. In this section, I will introduce several popular programs that can be applied to each step
mentioned above. Also, some widely used tools incorporating several features and functionalities
and complete analytical pipelines will be discussed.
2.3.1 Quality control tools
Most sequencing platforms generate a quality report as part of their functionalities, but
usually this report can only identify problems caused by the sequencer itself. Thus, there are some
other tools to control the quality of raw sequence data. FastQC (available online at
https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) is a classic tool which could provide
a wide range of information regarding the quality profile of reads including quality problems
originate either in the sequencer or in the starting library material, GC content, over-abundance of
adaptors and PCR duplication rate, etc. It accepts files in SAM/BAM or Fastq formats and is
compatible with all main sequencing platforms. Newly emerged FQC utilizes FastQC at backend
and integrates extended features like plotting and aggregating results of multiple sequence runs
into an interactive website [54].
Given the QC report, researchers can determine whether preprocessing steps need to be
carried out. AfterQC was designed to profile sequencing errors, analyze the overlapping for pairend sequencing data and cut adaptors [55]. Cutadapt [56] is capable of finding and removing
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adapter sequences, primers, poly-A tails and other types of undesired sequence. Trimmomatic [57]
includes a variety of processing steps for read trimming and filtering, but it is famous for
identification and removal of adapters.
2.3.2 Alignment tools
Many alignment tools have been established to reveal sequence conservation and variation
including Bowtie2 [58], BWA [59], SOAP3 [60], Eland (Illumina suite), NextGenMap [61], rHAT
[62], GSAlign [63], Arioc [64] and many others. Among these aligners, BWA, Bowtie (1 and 2)
are two of best suited ones for aligning large numbers of relatively short reads and most widely
used in NGS analysis.
Bowtie (1 and 2), SOAP (2 and 3), and BWA all use Burrows-Wheeler Transformation
techniques. Bowtie2 extends the original ultrafast, memory-efficient short read aligner to allow
gapped alignment using dynamic programming. It is also capable of aligning long reads to long
genomes. BWA is a short-read aligner which runs slower than Bowtie but allows indels and gaps.
The newest version BWA-MEM [65], which was incorporated as a component into BigBWA [66]
on a Hadoop cluster, can align long sequences up to megabases and support paired-end reads and
perform chimeric alignment. The implementation on Hadoop also substantially reduces
computational time, and increase fault tolerance.
Duplicated reads produced by PCR amplification during library construction always show
up after alignment. PCR duplicates containing an amplification-induced error may cause a variant
calling algorithm to misidentify the error as a true variant [67]. Thus, it is important to remove all
but one before calling variants. Picard MarkDuplicates (online version available at
http://broadinstitute.github.io/picard/) and SAMtools rmdup [68] are two main software used to
remove PCR duplicates. Picard is a set of command line tools written in Java. It identifies read
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duplicates (originate from the single DNA fragment) comparing sequences in the 5 prime positions
of both reads and read-pairs in a SAM/BAM file and produced a new SAM/BAM file with
duplicates marked. SAMtools is a library and software package for parsing and manipulating
alignments. It uses similar approaches for duplicate marking or removal as Picard but only keep
on read with the best quality. It is also able to convert other alignment formats, sort alignments,
call SNPs and small indels and view alignments in text.
2.3.3 Variant calling tools
Some popular variant calling programs for SNV and short indels include SAMtools [68],
GATK [69], MuTect [70], FreeBayes [71], Platypus [72] and VarScan2 [73]. GATK, short for The
Genome Analysis Toolkit, was originally designed to process sequencing data from Illumina but
expanded to handle data from a variety of platforms. It first produces the BAM file using BWA.
After some necessary manipulations aforementioned, it calls variants for each sample read, then
analyzes variants against known variants, and applies a calibration procedure to compute a false
discovery rate for each variant. The most updated version is GATK4, which includes Best
Practices workflow that is able to start with the raw sequencing data and provide and extends
variant calls into somatic, copy number and structural analyses and offers pipeline scripts for
workflows. VarScan2 is a platform-independent mutation caller that detects germline, somatic,
copy number and multi-sample variants. It uses a heuristic and statistical algorithm to classify
somatic status and detect variants in exome data from tumor–normal pairs according to the read
depth, base quality, variant allele frequency, and statistical significance, which reduces the impact
of confounding factors. MuTect performs a 3-step strategy which includes preprocessing of noisy
reads, a Bayesian classifier for detecting somatic mutations with very low allele fractions, and
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post-processing that tune filters to eliminate artifacts. SAMtools, as mentioned above, is also
widely used to call variants.
2.3.4 Annotation tools
Tools and packages for annotating variants include but are not limited to ANNOVAR [74],
SnpEff [75], SNPnexus [76], SnpSift [77]. ANNOVAR is able to perform annotations of variants
from diverse genomes with different levels based on their functional effects, conserved genomic
regions, predicted transcription factor binding sites, predicted microRNA target sites and predicted
stable RNA secondary structures. It provides both online server wANNOVAR [78] and standalone
program which can be run through command line. There different types of annotation supported
are gene-based, region-based and filter-based annotations. SnpEff annotates variants based on their
genomic locations and predicts coding effects of genes. It contains a pre-built database that
supports over 38,000 genomes, but also allows users to build their own database if needed. SnpSift
can also annotates genomic variants but is always used together with SnpEff to filter out significant
variants. SNPnexus is a web-based variant annotation tool that assists in assist in the selection of
functionally relevant mutations. The result contains for queried variants genomic regions, dbSNP
identifier (if any), gene/protein consequences, population data, etc.
2.3.5 Prioritization and filtration tools
Tools like VAAST2 [79], VarSifer [80], KGGseq [81], have be developed to filter and
prioritize variants. However, these tools rely on information in various databases thus can only
predict known variants. Prediction tools like PolyPhen-2 [82], SIFT [8], FATHMM [83],
PROVEAN [84] and many others use machine learning or statistical approaches to predict effects
of both known and novel variations.
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2.3.5.1 PolyPhen2 and SIFT
PolyPhen-2, available as standalone software or via the web server, predicts the damaging
effects of amino acid substitutions in human using a naive Bayes classifier. The prediction is based
on eight sequence-based and three structure-based features selected by an iterative greedy
algorithm. The program takes nonsynonymous variants and return prediction scores ranging from
0 to 1, which suggests the likelihood that a substitution is deleterious. Values close to 0 suggests
benign variants while values closer to 1 suggests damaging with a default value of 0.5.
SIFT uses sequence homology and physical properties of amino acid to predict the impact
of its substitutions on protein functions, which will help researchers to prioritize variants for further
study. The basic idea is that mutations occur at a highly conserved region tend to be deleterious.
Given a query sequence, SIFT searches the databases for related protein sequences and obtain an
alignment. The multiple alignment of query sequence from PSI-BLAST is then converted into a
position specific scoring matrix, which is a l×20 matrix where l is the length of the protein
sequence. Each entry 𝑝𝑐𝑎 , is the probability of AA a at position c of the protein where c ranges
from 1 to l and a is any one of the 20 AAs. 𝑝𝑐𝑎 is estimated using the following formula [85]:
𝑝𝑐𝑎 =

𝑁𝑐
𝐵𝑐
∙ 𝑔𝑐𝑎 +
∙𝑓
𝑁𝑐 + 𝐵𝑐
𝑁𝑐 + 𝐵𝑐 𝑐𝑎

(2.1)

where Nc is the total number of sequences in the alignment, gca is the sequence-weighted frequency
that amino acid a appears at position c in the alignment, fca is the pseudo-count that amino acid a
appears at position c and Bc is the total number of pseudo-count.
The score is then normalized on the most frequent AA being tolerated (highest pca). It
represents the probability that the amino acid change is tolerated. So, the scoring scheme of SIFT
is similar to that of PolyPhen-2, but with opposite meaning. A variant with a SIFT score less than
the cutoff value (usually set at 0.05) is predicted as deleterious. Because the prediction only
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depends on the sequence and does not require the information of protein structures, false positive
rate may increase if selected sequences are highly homogeneous. So, the result of SIFT also
includes a median sequence conservation value, ranges from 0 to 4.3, to show the diversity of
aligned sequences. A warning will appear if the median conservation value is greater than 3.0,
which means the confidence of the prediction is low.
2.3.5.2 FATHMM
FATHMM was originally constructed as algorithm that predicts the functional effects of
nonsynonymous variants on protein. Homologous sequences were searched to build Hidden
Markov Model (HMM) using HMMER3 where sequence conservation is interrogated.
SUPERFAMILY and Pfam were searched to identify relevant HMMs. The predicted FATHMM
score is essentially a log-odds score as shown in equation 2.2. Later on, pathogenicity weights
were incorporated to formulate a weighted scoring (equation 2.3) representing the overall tolerance
of proteins. It can be applied to both human and nonhuman species. In an unweighted prediction,
the magnitude of the effect is calculated using the following formula:
𝑢𝑛𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 = ln

𝑃𝑚 /(1 − 𝑃𝑚 )
𝑃𝑤 /(1 − 𝑃𝑤 )

(2.2)

where Pw and Pm are underlying probabilities for the wild-type and mutant amino acid residues,
respectively. For an improvement in human, a weighted prediction is used as follows:
𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 = ln

(1 − 𝑃𝑤 )(𝑊𝑛 + 1)
(1 − 𝑃𝑚 )(𝑊𝑑 + 1)

(2.3)

where 𝑊𝑑 and 𝑊𝑛 are the pathogenicity weights, representing the relative frequencies of
disease-associated and functionally neutral amino acid substitutions mapping onto the relevant
hidden Markov model, respectively. Prediction scores close to zero suggest neutral effect of the
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variant. However, scores below zero suggest that the substitution is unfavorable and scores greater
than zero suggest that a favorable effect of variants.
In the most recent development, FATHMM-MKL uses multiple kernel learning to integrate
different types of genomic annotation data into kernel matrices and apply support vector machine
to predict effects of both coding and noncoding variants [86]. FATHMM-XF employs the same
method but draws on an extended feature set which performs a better accuracy, especially on
noncoding regions [9]. In the new scoring schema, predictions are given as p-values in the range
[0, 1], where values above 0.5 are predicted as deleterious, and those below 0.5 are predicted to be
benign. P-values close to 0 or 1 are the highest-confidence predictions that yield the highest
accuracy.
2.3.5.3 PROVEAN
PROVEAN is an alignment-based algorithm that predicts the functional impact for all
kinds of protein sequence variations (single or multiple AA substitutions, in-frame indels). To
make predictions, the program requires the input of query protein sequence and observed protein
variations. It measures the change in sequence similarity of a query sequence to its homolog before
and after the introduction of an amino acid variation to the query sequence. This change in the
alignment score is used as the implication of the effect of sequence variation.
First, PROVEAN searches databases for a set of clusters of homologous and distantly
related sequences. Then a delta score, ∆(𝑄, 𝑣, 𝑆) is defined to represent the change in sequence
similarity. Q is the query protein and v is the variation with respect to its homologous sequence S.
So, for each S:
∆(𝑄, 𝑣, 𝑆) = 𝐴(𝑄 ′ , 𝑆) − 𝐴(𝑄, 𝑆)
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(2.4)

Then, an average delta score is computed over all S. To avoid bias due to over-representation of
groups of highly similar sequences in the database, homologous sequences were clustered in
advance and average delta score was taken over the representatives of each cluster. The equation
is given as follows:
𝑁

𝑁𝑐

1
1
𝑠𝑐𝑜𝑟𝑒 = ∑( ∑ ∆𝑐,𝑖 )
𝑁
𝑁𝑐
𝑐=1

(2.5)

𝑖=1

where N is the number of clusters in the supporting set, Nc is the number of supporting sequences
in the c-th cluster, and ∆𝑐,𝑖 is the delta score of the i-th supporting sequence in the c-th cluster.
This average is used as the final PROVEAN score. Low delta scores are interpreted as amino acid
variations leading to a deleterious effect on protein function, while high delta scores are interpreted
as variations with neutral effect on protein. The default cutoff value is set as -2.5.
Programs introduced in this part are only small portion of currently existed ones. Extensive
summaries of functional prediction tools and methods can be found elsewhere [11,87].
2.3.6 Resources for mutations, genes and pathways
Aforementioned tools could help researcher select potentially pathogenic variants from a
long list of identified variants. It is essential to link these variants to some biological processes or
diseases of interest according to information curated in databases. Variants in genes that are totally
unlinked to the known genes or pathways are largely neglected. Gene Ontology (GO) terms
annotate genes according to their cellular components, molecular functions and biological
processes. Pathway analysis may provide detailed functional insight into the connection between
genotype and phenotype, which is critical for understanding pathogenesis and thus developing
treatments [88,89]. Public databases like KEGG [90], Reactome [91] and many others are widely
used resources to understand how a set of genes interact with each other and function together to
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accomplish a specific task. Protein-protein interaction network is a good way to explore
relationships between different proteins. Different evidence of interactions (experimental, text
mining, predictions, etc) are marked with different colors. DAVID [92] is a popular web-based
tool to provide functional interpretation of user defined gene list. Databases like DrugBank [93]
can provide links between drugs and their targets (variants), which could help with exploring how
functional variants affect drug efficacy and adverse effects. OncoKB knowledge base for cancers
that annotates the biologic and oncogenic effects and prognostic and predictive significance of
somatic molecular alterations. It also provided summarized list of driver genes for various cancer
types [45]. ClinVar is an archive that collects, validates and curates evidence of clinical
significance for any type of genetic variants [94]. It is a great source to obtain effect of known
variants in clinic.
2.3.7 Complete analytical pipeline
Tools or software mentioned above can only perform one or a few closely related steps in
the workflow of WGS analysis. But it could be inefficient if one wants to conduct the complete
analysis as output from one program may be incompatible for the next tools then users need to
make modifications. Fortunately, there are some analytical pipelines that incorporate these tools
into a single workflow. Three recently developed genome analysis pipelines NGS-pipe [95],
Fastq2vcf [96] and SpeedSeq [97] were discussed in this section.
NGS-pipe is an automated framework for analyzing whole-exome/-genome and
transcriptome sequencing data. It incorporates tools for processing sequencing data, detecting
SNVs, indels and CNVs. In addition, for RNA-seq data, gene expression levels is estimated. To
ensure reproducibility, if any step of the pipeline failed or produced incomplete results, the whole
process is suspended and an error message is thrown.
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Fastq2vcf employs tools discussed above for each step to process, annotate and analyze
sequence variants in a single or parallel computing environment. FastQC and BWA are used for
quality control and sequence alignment. After formatting the data from SAM to BAM, a series of
post-processing steps are performed by employing Picard and GATK. The SAMtools, GATK and
SNVer [98] are invoked to call variants and generate VCF files. Finally, annotation of variants are
carried out by ANNOVAR and VEP [99].
SpeedSeq is an open-source platform that accomplishes alignment, variant detection and
functional annotation in a very rapid speed. It uses BWA-MEN to align paired-end FASTQ files
to the human GRCh37 reference genome. The duplication marking is assigned to Samblaster [100].
Then FreeBayes is run to detect SNVs and indels. LUMPY, SVTyper (A maximum-likelihood
Bayesian classification algorithm developed by the same team) and CNVnator are used together
to analyze and annotate SVs.
2.4 MOLECULAR PATHOLOGY OF PROSTATE CANCER
Accumulation of genomic alterations are hallmarks of cancer initiation and progression.
Over the past years, advances of sequencing technologies have enabled researchers to discover a
wide range of recurrent genomic alterations in PrCa. However, understanding the pathology and
developing a reliable biomarker is not easy because of complex interactions between multiple
genes/proteins, multiple implicated epidemiological factors and advanced patient age at diagnosis
[101]. This section briefly discusses genetic and molecular findings of PrCa.
2.4.1 Driver genes
A number of genes have been reported to be implicated in the development of PrCa. SPOP
is one of the most frequently mutated genes in PrCa. Recurrent mutations in SPOP define a subtype
of PrCa with notable molecular features including increased levels of DNA methylation,

23

homogeneous gene expression patterns and frequent overexpression of SPINK1 mRNA [102].
Blattner et al also demonstrated that mutations in SPOP serve as a driver event in invasive PrCa
in the mouse model by cooperating with the loss of PTEN, which is also a key tumor suppressor
in prostate cancer [103]. FOXA1 is a transcription factor that interacts with androgen receptor to
regulate prostatic gene expression [104]. Parolia et al found that alterations of FOXA1 fall into
three structural classes that differ in clinical incidence and genetic co-alteration profiles [105].
Moreover, majority of FOXA1 coding mutations are found in the DNA binding domain, which
decreases its DNA binding affinity [106]. ATM is a DNA repair gene that found most frequently
mutated in lethal cases of PrCa [107]. NKX3.1 is a tumor suppressor gene, the expression of which
was found to be decreased in high-grade prostatic intraepithelial neoplasia and this loss of
expression is strongly associated with hormone-refractory disease [108]. TP53 is the most frequent
mutated in various cancer types while in PrCa, it occurs less common. However, TP53 mutations
have been associated with lineage plasticity involving decreased expression of androgen receptor
and luminal differentiation genes [109] and combined loss of TP53 and RB1 can increase PrCa
resistance to therapies [110].
2.4.2 Genomic pathways
Androgen receptor (AR) signaling is pivotal in the normal development, function and
homeostasis of the prostate. An important finding regarding AR is the recurrent fusion of
androgen-responsive gene TMPRSS2 with oncogenic ETS transcription factor family ERG or
ETV1 resulting in aberrant expression of ERG or ETV1, which provides important implications for
understanding prostate cancer tumorigenesis [111]. GATA2 and FOXA1 serve as particularly
essential cofactors in AR signaling in PrCa cells by involving in androgen regulation of the PSA
gene and functioning as a pioneer transcription factor to bind to highly compacted chromatin [112].
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PI3K pathway functions in cell proliferation, cell transformation, protein synthesis, tumor
growth, etc. ATK, one of the major downstream targets of PI3K, can be activated by PI3K to
phosphorylate downstream targets for regulating various cellular functions [113]. The tumor
suppressor PTEN is an inhibitor for PI3K/AKT signaling pathway by regulating the expression of
HIF-1 and VEGF, which results in the inactivation of AKT and thus inhibiting tumor growth of
PrCa [114]. WNT signaling is a complex pathway that regulates the self-renewal of PrCa cells
with stem cell characteristics independently of AR activity. Therefore, Inhibition of WNT
signaling has the potential to reduce the self-renewal of PrCa cells and improve the therapeutic
outcome [115].
Many genes involved in DNA repair pathway are mutated in PrCa and they occur more
commonly in metastatic than localized prostate tumors. Among the most frequently mutated genes
are ATM, PARP1, BRCA1 and BRCA2 [109]. Cells evolved a complex signaling machinery to
recognize and repair DNA damage. This machinery includes several pathways with
complementary and partially overlapping functions. Different types of DNA damage trigger a
response from different branches of this complex system. Alteration in DNA repair genes can
cause DNA repair defects which may change the DNA damage response and result in genome
integrity, instability, followed by PrCa carcinogenesis and progression [116]. Also, findings
suggest that DNA repair genes and AR signaling pathway regulate each other. AR signaling can
increase expression of DNA repair genes and promotes PrCa radioresistance by accelerating repair
of ionizing radiation–induced DNA damage. In turn, one of the DNA repair proteins, PARP1, is
an important cofactor for AR transcriptional activity [117]. Such interactions are important for
therapies.
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Chapter 3 Materials and Methods
In this chapter, I formally describe methods and procedures used to preprocess VCF data,
analyze GSVs, evaluate their functional effects, and score pathogenic genes. An overview of
workflow is shown in Figure 3.1.

Figure 3.1: Overall workflow

3.1 DATA ACQUISITION AND PREPROCESSING
A total of 503 variant call format (VCF) files provided by The Cancer Genome Atlas
project were downloaded through National Cancer Institute’s data sharing platform Genomic Data
Common (https://portal.gdc.cancer.gov/). When navigate to this page, we search project name
‘TCGA-PRAD’ and on the result page, choose experimental strategy as wxs, workflow type as
Mutect2, and data format as vcf. Then, all 503 VCF files will show up which can be downloaded
as controlled data. Each file contains GSV information, including chromosome number, position
of the mutation, dbSNP identifier, reference base, mutated base, genotype, and reading depth, etc.
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for a paired sample which consists of a primary tumor tissue sample and a normal tissue sample,
from the same PrCa patient.
All VCF files were preprocessed and converted into more condensed CSV files for
downstream analysis. The preprocessing tool is mainly composed of three components. First, VCF
files are read and processed in Python with the package ‘pyvcf’. The first 8 data fields, listed
below, were directly extracted by going through each data line in the VCF file:
(i) numeric identifier (var_index)
(ii) chromosome number (chrom)
(iii) starting position of GSV (left)
(iv) ending position of GSV (right)
(v) reference base (ref)
(vi) mutated base (var_seq1)
(vii) mutated base (var_seq2; among var_seq1 and var_seq2, one is the mutated base and the other
is same as ref)
(viii) quality score (var_score, fixed at 28)
To ensure high quality of data and reduce possible effects of sequening error, GSVs with a read
coverage less than 5 or individual minor allele frequency less than 0.05 were removed.
In the second step, gene symbols, genomic regions and change type of amino acid for GSVs
in protein-coding regions were annotated based on the reference genome sequence GRCh38 and
the corresponding refFlat file, which is a tab-delimited text file holding information about gene
structure provided by UCSC Genome Browser. The columns in the refFlat file, as shown in Figure
3.2, represent successively
(i) gene name
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(ii) gene identifier
(iii) chromosome number
(iv) strand
(v) start positions of genes/transcripts
(vi) end positions of genes/transcripts
(vii) start positions of coding sequences
(viii) end positions of coding sequences
(ix) number of exons
(x) start positions of all exons
(xi) end positions of all exons

Figure 3.2: Example of refFlat files used to annotate GSVs
The position of each variant was compared with genomic regions in refFlat file and the
classification was determined according to the decision tree shown in Figure 3.3. Since one gene
may have multiple isoforms, the GSV could be annotated with multiple genes and genomic
regions. For GSVs located within the coding region, the change type of amino acid was determined
by comparing reference and variant AA. Since we only know ths position of GSVs, in order to
retrive the codon from the genome sequence, we need to identify the position of GSV on the
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specific codon. Therefore, we counted the number of bases from the first nucleotide in the coding
sequencing to the position of GSV. Then divided this number by 3 and recorded the reminder. If
the reminder is 0, the GSV occurs at the third position of codon, whicih means ref codon is formed
by the previous two bases in the genome and reference base at this point. If reminder is 1, the GSV
occurs at the first position of codon. So, we took the following two nucleotides. And if the reminder
is 2, previous and following bases will be used. The mutated codon is determined in the same way
but using mutated base instead of reference base. If reference codon and mutated codon code for
different AA, the change type is nonsynnymous. Otherwise, it is synonymous.

Figure 3.3: Decision tree used to classify genomic regions for GSVs
An additional column indicating the AA variation was also added. This column contains,
for each GSV that causes a nonsynonymous change of AA, the reference and mutated AA and the
position of this variation regarding the protein sequence. To find the position of the AA variation
in the protein sequence, we first obtained total length (L) of coding sequences (CDS) from the first
translated nucleotide to the current position of GSV. The position of AA change is calculated as
position of AA variation = {

⌊𝐿/3⌋
⌊𝐿/3⌋ + 1

where ⌊𝑥⌋ is the floor of 𝑥.
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if 𝐿 is a multiple of 3
otherwise

In the third step, GSV information and annotation in all 503 CSV files resulting from step
2 were merged to produce the final OncoMiner input file.
To improve efficiency, the original refFlat and reference sequence files were split by
chromosome for parallel processing. Each VCF file was also split before processing. The
multiprocessing module was used to achieve parallelization. After splitting the VCF file, variants
on various chromosomes can be processed in parallel following the three steps mentationed above.
Each core handles one chromosome at a time and moves on to the next chromosome if done.
Variants on all chromosomes are joined together to produce the final OncoMiner input file. The
preprocessing program was evaluated and optimized with 148 VCF files on a server with 32 cores
and 256 GB memory. The runtime behavior was tested using 1, 2, 4, 8, 16, and 24 cores
respectively to compare the speedup and efficiency, which are defined as
𝑆𝑝 = 𝑇1 ⁄𝑇𝑝 and 𝐸𝑃 = 𝑆𝑝 ⁄𝑝
where 𝑇𝑝 is the runtime with 𝑝 cores.
3.2 GENERATION AND EXPLORATION OF GSV LISTS
In order to compare GSV occurrences in tumor and normal samples, 3 disjoint sets of GSVs
T1N0, T0N1 and T1N1 were generated from preprocessed data using Python3, where T1N0 is the
set of GSVs found only in tumor sample but not in normal sample; T0N1 is the set of GSVs found
only in tumor sample but not in normal sample; T1N1 is the set of GSVs found in both. Statistics
of GSV counts and nucleotide change types were explored for tumor (T1N0+T1N1) and normal
(T0N1+T1N1) samples at various levels of genomic regions, including transcript, exon, intron etc.
Given a specific variant V, the subjects can be partitioned into 4 categories, SubT0N0(V),
SubT1N0(V), SubT1N0(V), and SubT1N1(V), where:
SubT0N0(V) = set of subjects who do not have variant V in the tumor and normal tissues,
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SubT1N0(V) = set of subjects who have variant V in the tumor but not normal tissue,
SubT0N1(V) = set of subjects who have variant V in the normal but not tumor tissue,
SubT1N1(V) = set of subjects who have variant V in both tumor and normal tissue.
Counts in the 4 categories for each GSV always add up to the total number of subjects included in
the study.
GSVs were further grouped by genes they belong to. For each specific gene, we counted
the number of distinct GSVs that fall on it for the tumor samples and then for the normal samples.
In this counting, each distinct GSV is counted only once regardless of how frequently it occurs
among the subjects. Alternatively, if we take the occurrence frequency of GSVs among the
subjects into consideration (e.g., if the GSV was found in 10 subjects, it would be counted 10
times), we can produce a tally GSV count for the gene. The tally counts for gene 𝑔 for the tumor
and normal samples will be denoted by 𝑇(𝑔, tumor) and 𝑇(𝑔, normal) respectively. We also
define the quantity
∆𝑇(𝑔) = 𝑇(𝑔, tumor) − 𝑇(𝑔, normal)

(3.1)

to be the difference between the observed tally counts of GSVs in gene 𝑔 in tumor and normal
samples. A high value of ∆𝑇(𝑔) indicates that 𝑔 is mutated much more frequently in tumor than
normal samples, suggesting possible involvement of 𝑔 in the disease.
3.3 MUTATIONAL LEVELS FOR DIFFERENT TYPES OF NUCLEOTIDE SUBSTITUTIONS
For all GSVs that fell on gene transcripts, we examined the 12 types of nucleotide
substitutions X→Y and compared how often they occur. Taking the background base frequencies
into consideration, we measure the level of the mutation X→Y using the fraction
𝑆XY =

Number of X → Y mutations in sample sequence
Number of base X observed in reference sequence
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(3.2)

The values of SXY will allow us to compare the different types of GSVs on tumor and normal
samples.
3.4 PREDICTION OF NONSYNONYMOUS GSVS AND PATHOGENIC GENES FOR CANCER
ASSOCIATIONS

Nonsynonymous GSVs (nsGSVs) were selected from the tumor list. GSV with multiple
annotated regions will be considered as nonsynonymous as long as it has one such annotation.
FATHMM and PROVEAN were employed to predict functional effects of nsGSVs.
GSV information was extracted from the merged tumor and normal lists to form the input
file for FATHMM-XF (latest version that supports GRCh38), which requires chromosome number
(string ‘chromosome’ and numeric number in separate columns), position of mutation, reference
and mutated bases and strand (all ones). An example of input file for FATHMM is shown in figure
3.4. The generated input files were submitted to webserver for predictions.

Figure 3.4: Example of FATHMM input file
PROVEAN requires two input files: the variation of AA change and protein sequence. AA
change for nsGSVs were already determined in preprocessing step. For the protein sequence, all
translated exon intervals of each gene were obtained from refFlat file. These intervals were used
to obtain pieces of sequence from reference genome. Then we concatenate these pieces and
translate into protein sequence according to the DNA codon table that maps nucleotide triplets into
the corresponding AA. From the beginning of concatenated DNA sequence, every three
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nucleotides are translated into an AA represented by a single character. Since multiple variants
may fall into the same gene, we group their AA variations in a single file and use the corresponding
protein sequence. An example of AA variation file for PROVEAN is shown in figure 3.5.

Figure 3.5: Example of amino acid variation file for PROVEAN
The standalone PROVEAN program was installed on our local high-performance
computing (HPC) platform, an IBM UNIX-based system with 2.53 GHz Intel Xeon processors.
We submitted all variations to the load sharing facility batch scheduler with high priority using
‘bsub’ command and distributed on 8 computing nodes of HPC with 5 cores, 3×106 kB file size
limit and 2-hour runtime limit allowed on each node.
Prediction scores from both tools were parsed according to their respective default value
(0.5 for FATHMM and -2.5 for PROVEAN) and incorporated into a supplemental data file listing
all the GSVs on protein-coding regions. Among other items, the file contains two columns, one
showing whether the GSV is classified pathogenic or benign by FATHMM and the second by
PROVEAN. If a variant is predicted as pathogenic by both, we refer to it as pathogenic variant.
An annotation tool SNPnexus [76] was also included to indicate the novelty of GSVs.
SNPnexus currently accepts query input data in three different forms (genomic position,
chromosomal region or dbSNP id). For input format of our data, we used genomic position form,
which requires six data columns, i.e ‘chromosome’, numeric number of chromosome, position of
variant, reference base, alternative base and strand. Columns 3 to 5 can be directly extracted from
OncoMiner input file as a data frame. ‘chromosome’ and strand (all ones) were generated and
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inserted to the dataframe at corresponding column index. Numeric chromosome number was
obtained from the ‘chrom’ column in OncoMiner input file by slicing the string using python. The
produced files were submitted to webserver, where users are allowed to select reference genome
that corresponds to the data. An example of input file for SNPnexus is shown in figure 3.6.

Figure 3.6: Example of input file for SNPnexus
Besides FATHMM and PROVEAN scores, the occurrence frequencies of the GSV among
the subjects in the tumor and normal samples is also an indicator of potential association with
PrCa. Let s(v, tumor) and s(v, normal) denote the numbers of subjects in whom the variant v
is observed. If the difference

∆𝑠 = s(v, tumor) − s(v, normal) is large, it would suggest v is

worth investigating for possible PrCa association. However, to screen out random noise, we only
evaluated those nsGSVs that occur in more than 1% of samples using the McNemar’s test [118]
with binomial approximation (equation 3.3):
𝑛

𝑛

𝑛
𝑛
𝑝 = ∑ ( ) 0.5𝑖 (1 − 0.5)𝑛−𝑖 = 0.5𝑛 ∑ ( )
𝑖
𝑖
𝑖=𝑏

(3.3)

𝑖=𝑏

where b is the number of GSVs that occurr in tumor but not normal tissues and n is the total number
of GSVs that occurr in tumor but not normal and occur in normal but not tumor. The calculated pvalues were further corrected for multiple comparison using Bonferroni adjustment [119], which
multiply the p-value by the number of total tests conducted.
After scoring each individual GSV with FATHMM, PROVEAN, and its occurrence
frequencies in our PrCa dataset, one can also comprehensively evaluate the pathogenicity of any
given protein coding gene by combining the evaluations of all the GSVs within. We propose two
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scoring functions: 𝑃𝑡(𝑔) and 𝑃𝑙 (𝑔) , both of which incorporate the average FATHMM and
PROVEAN ranks, as well as ∆𝑠 for all the GSVs contained in 𝑔. Furthermore, 𝑃𝑙 (𝑔) also takes
into account the coding length of genes. The scoring procedure consists of the following steps:
(1) Sort all variants according to their FATHMM and PROVEAN scores form the most pathogenic
to the least pathogenic respectively and for each pathogenic variant 𝑣, take the sum of two
ranks denoted as 𝑅𝑎𝑛𝑘𝑆𝑢𝑚(𝑣).
(2) calculate its RankScore as follows:
𝑅𝑎𝑛𝑘𝑆𝑐𝑜𝑟𝑒(𝑣) = 1 −

𝑅𝑎𝑛𝑘𝑆𝑢𝑚(𝑣)
2∗𝑛

(3.4)

where 𝑛 is the number of pathogenic variants.
(3) Group the pathogenic variants by their corresponding genes, which will be called pathogenic
genes from here on. For each pathogenic gene 𝑔, we calculate the two pathogenic gene scores
𝑃𝑡 (𝑔) and 𝑃𝑙 (𝑔) as follows:
𝑃𝑡 (𝑔) = ∑𝑣 in 𝑔 𝑅𝑎𝑛𝑘𝑆𝑐𝑜𝑟𝑒 (𝑣) ∗ [𝑠(𝑣, tumor) − 𝑠(𝑣, normal)]
1

𝑃𝑙 (𝑔) = ln 𝑙(𝑔) ∑𝑣 in 𝑔 𝑅𝑎𝑛𝑘𝑆𝑐𝑜𝑟𝑒(𝑣) ∗ [𝑠(𝑣, tumor) − 𝑠(𝑣, normal)]

(3.5)
(3.6)

where 𝑙(𝑔) is the total length of the coding regions for gene 𝑔. The value of 𝑙(𝑔) for each
gene was obtained from refFlat file by by adding the length of each coding exon. If a gene has
multiple isoforms, the longest coding region is used. Normalizing 𝑃𝑡 (𝑔) by the logarithmic
scale of 𝑙(𝑔) can counteract the effect of long coding sequence on number of GSVs and make
the subject counts between genes at similar scale regardless of gene size.
To demonstrate that the scoring functions 𝑃𝑡 (𝑔) and 𝑃𝑙 (𝑔) are effective in recognizing
PrCa-related genes, we need to compare the top-scoring genes with those that are well-known to
be related to PrCa. For this purpose, we compiled a list of PrCa-related genes from two sources.
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COSMIC cancer gene census [46] contains genes possess casual implications in cancers. The
whole list was downloaded from the website (https://cancer.sanger.ac.uk/census) and genes related
to PrCa were selected. Martinez et al. [120] constructed a compendium of cancer driver genes by
running state-of-the-art driver discovery methods. The PrCa driver genes were downloaded from
their IntOGen pipeline (https://www.intogen.org/search). On this website, I selected cancer type
prostate adneocarnocima. Then in the box of mutational cancer driver genes, a dowoloadable table
with all PrCa genes is available. Genes from two sources were merged to form our final list of
PrCa genes. It should be emphasized here that the genes obtained above are well-documented to
be PrCa-related, but it does not imply that all genes outside of this list are necessarily not related
to PrCa.
3.5 ENRICHMENT AND INTERACTION ANALYSIS OF TOP-SCORING PATHOGENIC GENES
Using the scoring functions in (3.5) and (3.6) respectively, 2 sets of top-scoring 1%
pathogenic genes were selected. The union of two sets forms the final gene list for bioinformatics
analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analyses were performed in R using clusterprofile. The code is as follows:
library(clusterProfiler)
library(org.Hs.eg.db)
select_feature=read.table("differentially_mutated_genes.txt",header=F,sep=",")
common=select_feature[[1]]
entrezid=bitr(common,fromType = "SYMBOL", toType = "ENTREZID",OrgDb = "org.Hs.eg.db")
ego <- enrichGO(OrgDb="org.Hs.eg.db", gene = entrezid$ENTREZID, ont = "BP",
pAdjustMethod="BH",pvalueCutoff = 0.05, readable= TRUE)
ekk <- enrichKEGG(gene= entrezid$ENTREZID,organism
stMethod="BH",qvalueCutoff = 0.05)

= 'human', pvalueCutoff = 0.05,pAdju

Enrichment terms are used to illustrate possible pathways and molecular functions these genes
may be enriched in. The Search Tool for the Retrieval of Interacting Genes (STRING:
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https://string‑db.org) was used to construct protein-protein interaction (PPI) networks, which was
visualized and analyzed by Cytoscape [121]. On the homepage of STRING, choose multiple
proteins on the left panel and put the list of genes/proteins into the box appear in the search box.
Once submitted, analysis of network and export options become available on the result page.
Another PPI network was constructed using proteins of PrCa and pathogenic genes. In order to
analyze interactions between proteins, the interaction file was dowoloaded and a list of the
prominent pathogenic genes that have four or more direct interactions with PrCa genes were picked
out. Interactions between PrCa genes were also removed in advance. The refined interaction file
was imported into Cytoscape to visualize associations between these pathogenic and their
interacting PrCa genes.
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Chapter 4 Results
In this chapter, I present all results related to this work. Supplementary files and basic
information

of

dissertation

are

stored

at

the

following

bioinformatics

repository:

https://datarepo.bioinformatics.utep.edu/getdata?acc=NJHD3ANPBIJW614. All codes can
be found at Github repository https://github.com/bofei-wang/ProstateCancer_TCGA_VCF.
4.1 COMPILED DATASETS OF GSVS, GSV-GENES, AND PRCA GENES
The preprocessing script has been successfully implemented. As expected, using multiple
cores substantially reduced overall runtime. The average runtime with various cores is displayed
in Figure 4.1. As the number of cores increases, the speedup is quite substantial. The highest
speedup achievedwas 4.001 using 24 cores. The overall efficiencies using multiple cores were also
evaluated and shown in Figure 4.2. To compare the observed efficiencies, we set up a baseline
efficiency for each core used as 1/p as if no speedup was achieved. Noting the speedup-efficiency
trade-off, we decided to process all 503 using 8 cores. The overall runtime was about 40.6 minutes
with average runtime=4.85 seconds/file, speedup=3.144, efficiency = 0.393).
After preprocessing, annotation, and compilation of the 503 WES datasets from PrCa
patients, a total of 99856 distinct GSVs were collected of which 99761 were found in tumor
samples and 4017 in normal, with 3922 in both. We have put together a large data file
(S1.GSV_distribution.csv) with 99856 rows (GSVs) by 1021 columns organized as follows:
(i) The first five columns (A – E) contain chromosome number (chrom), start (left) and end (right)
positions of GSV, and the reference (ref_seq) and mutated (alt) bases.
(ii) The next four columns (F – I) contain subject counts SubT1N1, SubT1N0, SubT0N1,
SubT0N0. For a GSV in any particular row, these four counts respectively indicate how many
subjects have this variant in both tumor and normal samples, exclusively in the tumor sample,
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Figure 4.1: Average runtimes for test VCF files using multiple cores
exclusively in the normal sample, and in neither. These four counts always add up to the total
number of subjects.
(iii) Columns J – L were obtained using SNPnexus showing the dbSNP identifier (if exists),
overlapped gene and genomic region annotation.
(iv) Columns M – O were obtained from our preprocessing script showing the gene name, genomic
region and change type of amino acid if the GSV occurs in protein-coding region.
(v) The remaining 1006 columns indicate the presence (1) or absence (0) of each GSV in the tumor
and normal samples among the 503 files.
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Figure 4.2: Average efficiencies for various cores
The total collection of GSVs in the samples fell on 17036 genes (S2.
GSV_gene_distribution.csv), which will be referred to as GSV-genes from here on. All of them
contain some GSVs from the tumor samples, but only 3120 are involved in normal samples. The
number of GSVs within each of these gene was recorded for the tumor and normal samples in each
patient and the difference was calculated. This generated a matrix with 17036 rows (genes) by
1520 columns organized as follows:
(i) The first three columns (A – C) contain chromosome number, gene symbol and indicator
showing whether it is a protein coding gene (Yes) or not (No).
(ii) The next four columns (D – G) contain distinct and tally counts for tumor and normal samples.
(iii) Columns (H – K) contain numbers of GSVs in coding regions and nsGSV for tumor and
normal samples.
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(iv) The remaining 1509 columns show the count of GSVs in tumor and normal samples among
the 503 files and the difference between each pair of samples.
Among the GSV-genes, 15943 are protein coding, all of which contain variants in the
tumor samples but only 2981 have variants in normal samples. Supplementary file
S3.predict_GSV_CDS.xlsx contains a listing of 33369 GSVs in our dataset that fall on protein
coding regions. Among these, only 11 GSVs were found in normal but not in tumor samples. All
of the remaining 33358 GSVs, which include 9490 synonymous, 22430 nonsynonymous, and 1438
nonsense substitutions, occur at least once in the tumor samples. More detailed descriptions of the
contents in S3 will be provided in later sections.
A total of 82 PrCa driver genes were obtained from Integrative OncoGenomics. Another
set of 28 PrCa-related genes was obtained from COSMIC cancer gene census. The union of the
two sets forms a list of 102 PrCa genes (see ‘Listed PrCa genes’ tab in S3), which is used in this
research to assess the effectiveness of different scoring schemes in selecting PrCa-related genes.
In the rest of this dissertation, any gene within this list is called a ‘listed PrCa gene’ (LPC gene)
and any gene outside this list a ‘non-LPC gene’. We reiterate here that a non-LPC gene only means
that, to date, there is not a sufficient number of studies in the published literature confirming its
association with PrCa, but does not imply that the gene is necessarily not PrCa related.
4.2 MUTATIONAL LANDSCAPE
4.2.1 Overview
From the compiled supplementary data files, we can obtain summary statistics of GSV
counts considered individually or grouped by genes. Figure 4.3 displays the GSV counts of tumor
and normal samples in each patient file sorted by tumor counts with log transformation. However,
y-axis shows the original values.
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Figure 4.3: Tumor/normal GSV counts in patient files
4.2.2 Different types of genomic regions
Table 4.1 below summarizes distinct as well as tally GSV counts in different types of
genomic regions. The distinct count simply holds the distinct number of GSVs at each level
(number of rows in data) while the tally count takes into consideration the number of subjects with
each GSV. For both tumor and normal samples, almost 98% of the GSVs were within gene
transcripts regions. Within transcripts, the percentages of GSVs on exons are much higher in tumor
than normal samples (41% versus 23%). Similar differences between tumor and normal samples
were observed for the percentages of GSVs in protein coding regions, and of GSVs causing
nonsynonymous codon changes.
Table 4.1: GSV counts in tumor and normal samples at various types of genomic regions,
along with the tumor/normal ratio.
Distinct GSV counts (d)

Tally GSV counts (t)

Tumor

Normal

Tum/Nor

Tumor

Normal

Tum/Nor

Filtered dataset

99761

4017

24.83

103741

4727

21.95

Intergenic

2180

119

18.32

2456

143

17.17
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Gene transcripts

97581

3898

25.03

101285

4584

22.10

Introns

57311

3012

19.03

60038

3606

16.65

Exons

40270

886

45.45

41247

978

42.17

Untranslated

6912

348

19.86

7306

398

18.36

Protein coding

33358

538

62.00

33941

580

58.52

nonsynonymous

23868

387

61.67

24281

417

58.23

4.2.3 Mutations in tumor samples tend to become A/T-rich
There are 12 possible types of single nucleotide substitutions, including the four transitions
(A↔G, C↔T) and eight transversions (A↔C, A↔T, C↔G, G↔T). As shown in Figure 4.4,
within gene transcripts of all GSV-genes in the tumor samples, transitions constituted 56.1% of all
GSVs and this percentage increased further to 65.4% in exons. The split between transitions and
transversions was quite even: 49.6% vs. 50.4% in introns. In contrast, transitions made up only
38.2% in the normal samples, and remain around the same, 34.5% and 39.3%, in exons and introns
respectively.
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Figure 4.4: Transition/transversion splits in transcripts, intron and exon among tumor(a)
and normal(b) samples
The difference in transition percentages between the tumor and normal samples prompted
us to examine the 12 types of substitutions more closely. In the tumor samples, the transitions
G→A, C→T, were most overrepresented, forming respectively 22.7% and 19.8% of all GSVs.
However, other two transition A→G, and T→C were actually below average in frequency. In
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normal samples, no such overrepresentation was observed, but A↔T substitutions were highly
underrepresented in both directions.
Noting that if mutation occurs randomly, a base X with higher frequency in the sequence
would be expected to have a higher number of mutations changing it to a different base. The
observed number of the 12 types of substitutions in the tumor and normal samples are given in the
Table 4.2 below. From these, we obtain the mutation levels 𝑆XY as shown in Figure 4.5.
Table 4.2: Base counts on GSV-gene transcripts and observed number of 12 different
substitutions on tumor and normal samples.
Total base
Tumor
Normal
count
A
T
C
G
A
T
C
G
A 418377428
3013
1953
6611
60
435
379
T 419843455 2946
6623
2192
50
348
543
C 298369704 15810 19321
2647
342
412
323
G 299045605 22197 11728 2540
350
390
266
From the mutation levels in the Figure 4.5, it can be seen that
1. Overall mutation levels for all 12 substitutions are higher in tumor than in normal
samples.
2. In tumor samples, the strong bases C and G have much higher mutation levels than the
weak bases A and T. While mutation levels are much lower in normal samples, similar mutation
level differences among the strong and weak nucleotides are observable in the normal samples but
to a much less extent.
3. In tumor samples, both C and G have higher tendency to mutate to A or T than to their
own complementary bases. This preference is not obvious in normal samples.
4. Mutational levels in exon are extremely higher than that in intron for both tumor and
normal samples.
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Figure 4.5: Mutational levels (𝑺𝐗𝐘 × 𝟏𝟎𝟔 ) in gene transcripts, exon and intron regions
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4.2.4 Tally counts of GSVs reveal highly mutated GSV-genes
For each gene, the tally count of GSVs on a gene reflects the abundance of mutations on
it. We use ∆T to measure the difference of tally counts between tumor and normal samples. The
value of ∆T ranges from 0 to 279 over the collection of GSV genes. The top ten with highest ∆T
are listed in Table 4.3 below.
Table 4.3: Top 10 GSV-genes with the highest ∆T
Tumor Normal
Chr
∆𝑇
Gene functions
count
count
Chr19
291
12
279
Regulation of the immune response
Negatively regulates the plasma
membrane cation channel TRPM8
Chr7
TCAF2
195
3
190
activity; Promotes prostate cancer cell
migration stimulation in a TRPM8dependent manner
Establishment and function of specific
Chr5
PCDHA1
136
1
135
cell-cell connections in the brain
Associated with autosomal recessive
cerebellar ataxia; transmission of
Chr6
SYNE1
115
3
112
mechanical forces across the nuclear
envelope
Adhesion template for the assembly of
Chr2
TTN
103
0
103
contractile machinery in muscle; kinase
activity
Chr1 CROCCP2
101
3
98
Pseudogene
Signal transduction pathways of the
Chr21
TPTE
103
6
97
endocrine or spermatogenic function of
the testis
Organization of myofibrils during
Chr1
OBSCN
102
6
96
assembly; mediate interactions between
the sarcoplasmic reticulum and myofibrils
Chr19
MUC16
90
0
90
Form a barrier to protect epithelial cells
Establishment and maintenance of specific
Chr5 PCDHGA2
85
0
85
neuronal connections in the brain
Gene
symbol
KIR2DS3

4.3 PREDICTING PRCA-ASSOCIATED NSGSVS
As exonic nonsynonymous mutations regions are more likely to cause biological changes
associated with diseases [122], we focused on 22430 nsGSVs that occur at least once in the tumor
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samples to analyze whether they are benign or pathogenic using two functional prediction tools
FATHMM and PROVEAN, which predict variant effects by multiple kernel learning and
difference between alignment scores respectively. The prediction results were added to
corresponding GSVs in supplementary file S3.
4.3.1 FATHMM and PROVEAN prediction
For those 22430 nsGSVs, 11152 were predicted pathogenic by FATHMM, 12352 by
PROVEAN, and 8474 by both with their respective default cutoff values 0.5 and -2.5. We will
refer to these 8474 nsGSVs as pathogenic, of which 5238 were found novel when checked against
the known GSVs in dbSNP.
4.3.2 Five GSVs showed statistical significance by frequency-based prediction
There were only 11 nsGSVs that occur in 6 or more subjects (> 1% of 503). Comparing
their occurrence frequencies in the tumor and normal samples, five nsGSVs showed statistically
significant associations with PrCa (Table 4.4) based on the McNemar test.
Table 4.4: GSVs statistically associated with PrCa (Adjusted p < 0.05 in McNemar’s test)
Chr
Position
Gene
FATHMM PROVEAN Adjusted p
dbSNP
7
100956292
MUC3A
-0.781
0.0013
rs1162418239
10
50068136
WASHC2A
0.0561
-1.601
0.0215
Novel
15
82434465
GOLGA6L9
0.0530
-0.0430
rs1367026482
17
41026893
KRTAP1-5
0.0124
2.800
0.0215
rs746834174
17
49619070
SPOP
0.9438
-11.628
0.0430
rs1057519968
4.4 PATHOGENIC GSV-GENES POSSIBLY ASSOCIATED WITH PRCA
The 8474 pathogenic nsGSVs span 5357 genes, which will be referred to as pathogenic
genes. These pathogenic genes cover 63 LPC genes. Most pathogenic genes contain only one
single pathogenic nsGSV but the number goes up to 37. The three genes with the highest count of
distinct pathogenic nsGSVs were TTN (37), TP53 (27) and SPOP (23). TP53 and SPOP are wellknown cancer driver genes in PrCa [102,123]. TTN was reported to be frequently mutated in
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various cancers including PrCa. However, TTN is rarely indicated as a tumor-associated gene
[124]. The high mutation frequency may largely due to its giant size. This finding inspires us to
take the length of genes into consideration and design a scoring function that incorporates the
average FATHMM and PROVEAN ranks, tally counts of GSVs and the coding length of genes.
A supplementary file S4.pathogenic_genes.xlsx contains all pathogenic genes and specific
aforementioned information including:
(i) Number of distinct pathogenic nsGSVs in this gene.
(ii) Number of distinct coding GSVs in this gene.
(iii) ∆𝑇 score.
(iv) Length of coding sequencing.
(v) 𝑃𝑡 (𝑔) and 𝑃𝑡 (𝑔) rank.
(vi) 𝑃𝑙 (𝑔) and 𝑃𝑙 (𝑔) rank
(vii) The last 2 columns indicate whether the gene is contained in the the two sources of LPC
genes.
According to two scores given by equations (3.5) and (3.6), we selected 1% of pathogenic GSVgenes from each respectively and took the union of 2 sets which resulted in 61 top-scoring
pathogenic genes contained in the ‘high_patho’ page of Supplemental file S4. Among the topscoring pathogenic genes, 12 are LPC genes.
4.5 BIOINFORMATICS ANALYSIS
The final gene list selected for bioinformatics analysis consists of 61 high-scoring pathogenic
genes selected by the scoring functions 𝑃𝑡 (𝑔) and 𝑃𝑙 (𝑔) as defined in (3.5) and (3.6).
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4.5.1 GO analysis
According to the GO term annotations, these 61 high-scoring pathogenic genes were
enriched in 327 terms in biological process (BP), 50 terms in molecular function (MF) and 50
terms in cellular component (CC). The top 10 terms in each category are shown in Figure 4.6. The
number at the end of each shows the gene ratio (observed/background) of each term. This result
indicated that these genes were mainly involved in the heart and muscle development,
transmembrane channel activity, and muscle contraction, etc.
4.5.2 Pathway enrichment
Enriched pathways in Figure 4.7 revealed that the high-scoring pathogenic genes were
primarily involved in cardiac functions and diseases, focal adhesion, signaling pathways, and
various cancers including PrCa.
4.5.3 Protein-protein interaction networks
The PPI network constructed for the 61 high-scoring pathogenic genes (see supplementary
file S4) is shown in Figure 4.8. The network contains 61 nodes and 122 edges with average node
degree 4. In the network involving pathogenic genes and LPC genes, we found 27 genes (see Table
4.5) interacting with 4 or more LPC genes, where 15 are non-LPC genes. These 15 pathogenic
genes were picked out and their interactions with LPC genes were visualized in Figure 4.9. Table
4.5 lists 27 pathogenic genes that have four or more direct interactions with LPC genes.
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Figure 4.6: Top 10 terms of GO annotation for BP, CC and MF

51

Figure 4.7: KEGG pathway enrichment analysis
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Figure 4.8: Protein-protein interaction network of 61 high-scoring pathogenic genes
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Figure 4.9: Interactions between 15 high-scoring pathogenic non-LPC genes (yellow) with
LPC genes (blue). Interactions among the blue nodes are not shown.
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Table 4.5: Top-scoring pathogenic genes with 4 or more direct interactions with LPC
genes. In boldface are those that are also LPC genes themselves.
Gene
TP53
CTNNB1
SMAD4
KMT2D
ATM
KMT2C
IDH1
FOXA1
SPOP
NKX3-1

Interaction
66
43
33
29
28
27
21
19
18
14

CSMD3
TRRAP

13
12

BRAF
CHD4

11
10

VWF
LRP1B
EPHB1

9
6
6

HERC2

6

MCM3
SPTA1
SALL1
HERC1

5
4
4
4

RYBP

4

TTN

4

CHD5

4

MYH6
FAT3

4
4

References
LPC gene
LPC gene
LPC gene
LPC gene
LPC gene
LPC gene
LPC gene
LPC gene
LPC gene
Prostatic tumor suppressor gene, downregulated or loss of
expression in advanced PrCa [108,125]
Highly mutated and differentially methylated in PrCa [126]
Potential tumor-suppressive role in breast cancer [127]; regulate
TP53 in lymphoma [128]
LPC gene
Co-repress early growth response activities that are involved in the
progression of PrCa [129];
Increased plasma concentrations in various cancer types [130]
LPC gene
Overexpression associated with a favorable prognosis for glioma;
tumor promoter in medulloblastoma [131]
Promising drug target for immunotherapeutic treatments in breast
cancer development and pathogenesis [132]; mutations detected in
leukemia cells, gastric and colorectal carcinomas [133]
Independent prognostic factor for hepatocellular carcinoma [134]
Mutated in all stages of small cell lung cancer progression [135]
Tumor suppressor in breast cancer [136]
High level of expression leads to greater survival in kidney cancer,
head and neck cancer, and pancreatic cancer [133]
A deleted region harboring RYBP and other genes in PrCa suggests
cooperative suppressive role [137]
Frequently mutated in various cancers; rarely reported to be
functionally associated with cancers [124,138]
Tumor suppressor: mutated, deleted or silenced in a number of
malignancies [139]
Cardiac marker gene, sick sinus syndrome susceptibility gene [140]
LPC gene
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4.6 PYTHON SCRIPTS AND SUPPLEMENTARY FILES
Four major python scripts have been developed to perform the following tasks in this
research:
A. Convert VCF files into CSV file and annotate variants with gene names, genomic regions and
change type of AA. This is achieved in parallel processing by spliting VCF files according to
chromosomes and distributing the work of extraction and annotation on subfiles to different
cores.
B. Merge GSVs from all samples into a single list, construct the binary matrix that mark the GSV
occurrences in each sample, and then calculate calculate their subject counts.
C. Select nsGSVs and generate input for FATHMM and PROVEAN; parse prediction results and
add them to the GSV list.
D. Group GSVs by genes, obtain CDS length of each gene and calculate their pathogenic scores,
and then select top-scoring genes for bioinformatics analysis.
All the above codes are publicly available at Github repository
https://github.com/bofei-wang/ProstateCancer_TCGA_VCF.
These codes are also being incorporated into the next version of OncoMiner to be released at the
OncoMiner website (oncominer.utep.edu).
For

the

various

S1.GSV_distribution.csv,

steps

in

our

data

analysis,

S2.GSV-gene_distribution.csv,

four

supplementary

files

S3.predict_GSV_CDS.xlsx,

and

S4.pathogenic_genes.xlsx were organized and they are available at our bioinformatics resporitary
https://datarepo.bioinformatics.utep.edu/getdata?acc=NJHD3ANPBIJW614.
1. S1 contains information of all distinct GSVs collected from 503 subjects with a binary
matrix indicating their occurrences in each patient’s tumor and normal samples.

56

2. S2 contains information of all GSV-genes, various levels of GSV counts, ∆T, 2 columns
indicating the LPC genes and a matrix indicating the number of GSVs on that gene row in
the tumor and normal samples together with the difference in between for each subject.
3. S3 comprises two sheets. The first one contains information of coding GSVs and prediction
results from FATHMM. AA change and PROVEAN predictions for nsGSVs are also
included. The last column indicates whether this GSV is predicted as pathogenic by
FATHMM (F), PROVEAN (P), both or neither. The second sheet contains PrCa-associated
genes compiled from COSMIC and reference [120].
4. S4 also has two sheets. The first one contains information of all pathogenic genes and two
pathogenic scores for each gene, etc. The second sheet contains highly pathogenic genes
selected based on two scoring functions and the number of PrCa genes they interact with.
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Chapter 5 Discussions
Rapid development and extensive use of high-throughput sequencing technologies in
genomics make it especially important to analyze those big data computationally. Comparing with
existing prediction tools, the input files for MutSig include a mutation table in the format of
Mutation Annotation File (MAF), a coverage table indicating the number of nucleotides sequenced
for mutation calling in each patient and each gene and a covariates table that contains expression
level and replication time of each gene. However, converting VCF files to MAF are not always
easy and one usually does not have information for ‘categ’ required in MAF and coverage files.
Polyphen, SIFT and MutationTaster use GRCh37 as reference genome which does not match the
one in our data (GRCh38). Mutation Assessor cannot accept VCF files. Therefore, to the best of
our knowledge, the proposed workflow is first approach to process a batch of VCF files and
comparatively analyze cancer-related GSVs.
5.1 PREPROCESSING
In this study, we use computational approaches to analyze GSVs and related genes from a
large cohort of PrCa patients. The original dataset was preprocessed to extract necessary GSV
information and each GSV was annotated with corresponding gene name, genomic region.
Parallelization was achieved by splitting data by chromosome and distributing work to different
cores. The best speedup achieved was less optimal probably due to several reasons. First, according
to Amdahl's law [141], the serial part in program would limit the speedup to the reciprocal of the
fraction of serial portion in the code. When checking the runtime using 1 core, the serial proportion
was about 17.5% of the overall runtime, which limited the best speedup at 5.7. Second, I/O issues
and the communications between independent processes can also increase the runtime. Therefore,
the observed speedup was below the ideal value. Finally, a decrease in efficiency was observed
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with increasing number of cores. This is because not all cores were fully utilized during the whole
process when using multiple cores as different chromosomes contain different numbers of GSVs.
5.2 MUTATIONAL LANDSCAPE AND DISCRIMINATING GSVS
At the variant level, tumor sample was predominantly composed of transitions and the
percentage further went up when restricted to exonic regions. This is largely due to the extremely
high level of transitions G → A, C → T and such observations were also reported in other cancer
types [142,143].

In addition, transversions G→T, C→A also showed much higher levels in

tumor samples, which also stands when the background base frequencies were taken into
consideration, suggesting their possible impact in cancer development. As previous studies have
suggested that DNA methylation at CpG sites could cause mutations leading to genetic disease
[144], it would be of interest to further investigate the mutations on G and C bases and their
possible ties to cancer.
The McNemar test revealed five discriminating nsGSVs (see Table 4.4) that showed
significantly higher occurrence frequencies in tumor than normal samples. In particular, the one at
position 50068136 on chromosome 10 within the WASHC2A gene has not been previously reported
in the dbSNP database.
Another noteworthy nsGSV, designated rs1057519968 and located at base 49619070 on
chromosome 17, is predicted to be highly pathogenic by both FATHMM and PROVEAN. It falls
on position 20187 of the famous PrCa driver gene SPOP and caused the W131G mutation in the
protein. This consistency across different predictions strongly supports the involvement of this
GSV in PrCa. It is also curated as ‘likely pathogenic’ in ClinVar [27], but how this mutation
contributes to the disease remains to be understood.
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5.3 FUNCTIONAL EFFECT PREDICTIONS
Functional predictions by FATHMM and PROVEAN revealed 8474 possibly deleterious
nsGSVs. Among nsGSVs, 311 GSVs did not get predicted by FATHMM. These include 10 GSVs
on chromosome X which were not predicted because FATHMM was designed to work on
autosomal chromosomes only. The explanation for the remaining ones may come from the minor
gap between different patch of GRCh38. Running PROVEAN on HPC is burdensome due to the
large number of AA variations and size of protein sequences. The work was submitted with ‘bsub’
but memory needed to be released every 1000-2000 proteins. Variations on some giant proteins
were manually submitted to the online version as they reached the maximum memory allowed on
our local server. It should be noted that other existing traditional tools like Polyphen and SIFT
were not used in our analysis as they were based on an earlier version of reference genome
GRCh37, thus not applicable to our data.
From the compiled gene lists, top 10 genes were identified based on their ΔT scores (i.e.,
the occurrence frequency difference between tumor and normal tissues across all patients). In line
with published literatures, SYNE1 and MUC16 were found to be frequently mutated in PrCa [123].
Mutations in SYNE1 may also increase the risk of invasive ovarian cancer [145]. MUC16 encodes
a high molecular weight glycoprotein which poses a high risk of residue change. It is normally
expressed by epithelium reproductive organs and is a well-known serum marker for ovarian cancer
[146]. Studies have shown that overexpression of MUC16 induced proliferation, migration and
invasion of epithelial ovarian cancer through the PI3K/AKT signaling pathway [147] and p120catenin cytoplasmic translocation [148]. Lakshmanan et al. [149] found that it regulates TSPYL5,
leading to decreased tumor suppressor activity of p53, which in turn promotes the lung cancer cell
growth. Many studies have also observed deregulation of other members of mucin family in
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various cancer types [146,150]. Aberrant expression of tumor-associated mucins induces cell
invasion, migration and extravasation via different pathways.
OBSCN and TTN were identified as highly mutated genes in various cancer types,
especially the breast cancer [151,152], which shares some cancer driver genes with PrCa, like
BRCA1 and BRCA2. Mutational event in OBSCN were implicated to affect GPCR, Ras, p75 and
Wnt signaling pathways which regulate cell proliferation and differentiation in breast cancer [151].
TPTE is a cancer-testis antigen expressed only in tumor tissue not normal testis. It is a
homolog of tumor suppressor gene PTEN. PTEN is a well-known prostate cancer-associated gene
[153], which suggests that mutations in TPTE is highly likely to contribute to the development of
PrCa. Although few studies suggesting the role of TPTE in cancer development, its absence in
healthy tissues, homolog to PTEN and specific expression in testis [154] make it an attractive
candidate for PrCa biomarker.
KIR2DS3 is a member of killer-cell immunoglobulin receptor (KIR) family, which plays a
crucial role in immune response. Various studies reflect divergent effects of KIR genes in cancers
[155], thus their functions to tumorigenesis remain largely unknown. The remaining candidates in
the list, including PCDHA1 and TCAF2, have not been reported to be involved in any cancer
development process, to the best of our knowledge. PCDHGA2 can regulate Wnt signalling and
growth properties in normal and cancer cells [156].
The nonfunctional pseudogene CROCCP2 is possibly a false positive as it is barely
reported to involve in biological activities. However, the other genes in Table 4.3 are promising
cancer-associated genes. For some of them, their associations with PrCa remain largely unknown,
but can be further explored.
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5.4 SCORING FUNCTIONS
According to the rank sum of FATHMM and PROVEAN scores, the top 1% (54)
pathogenic genes overlapped 9 LPC genes. When the same number of top genes selected according
to occurrence frequency, only 4 LPC genes were included. The modest performance of these
methods independently prompts us to develop some scoring functions that integrate all these
prediction results. The 𝑃𝑡 (𝑔) incorporates rank score of FATHMM and PROVEAN and the
difference of subject counts between tumor and normal samples.
Noting that the length of CDS may affect the number of nsGSVs detected on the gene, a
normalization factor involving the length of CDS was added to 𝑃𝑡 (𝑔). Factors including CDS
length itself, log and square root of CDS length were tried out and log transformation outperformed
the others, thus was selected to normalize 𝑃𝑡 (𝑔) and form the function 𝑃𝑙 (𝑔). As the two scoring
functions showed equavilant performance in detecting PrCa genes, both were used in selecting top
pathogenic genes.
The pathogenic genes selected by the combination of two scoring functions cover 12 LPC
genes, which validates its effectiveness in computationally selecting potentially pathogenic genes
from a large set of genes. TP53 and SPOP are top two pathogenic genes identified by 𝑃𝑡 (𝑔) and
𝑃𝑙 (𝑔). These two genes have been extensively recognized as frequently mutated genes in PrCa
[102,123], and TP53 is a recognized tumor suppresser gene across various cancer types [120,157].
5.5 BIOINFORMATICS ANALYSIS
GO term analysis of top 1% pathogenic genes revealed that these genes were largely
enriched in the process related to the formation of cardiac muscle tissue, heart morphogenesis and
contraction, and gated channel activities. There are increasing evidence suggesting that ion
channels and calcium channels contribute to many cell behaviors that could be important to tumor
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progression and metastasis including migration, invasion, adhesion, etc [158, 159]. Heart
contraction is a process initiated by activation of voltage-dependent Ca2+ channels [160] and
abnormal functions like heart failure with reduced ejection fraction has a higher likelihood of
cancer development [161]. Thus, mutations in these genes may cause dysregulation of cell-cell
adhesion and cardiac muscle abnormity which initiate tumor cell development and migration.
Enriched pathways were mainly regarding to cancers, cardiomyopathy and signaling
pathways. Proteoglycans, as a functional constituents of extracellular matrix binding to various
growth factors and adhesive factors, have been associated with cancer pathogenesis [162]. Proteins
in calcium signaling pathway are important in regulating cell cycles such as proliferation, gene
transcription and cell death by controlling Ca2+ pumps, Ca2+ channels, etc. [163]. Shapero et al.
[164] in 2001 identified a prostate-specific gene which is homologous to the transient receptor
potential family of Ca2+ channel proteins. Increased focal-adhesion kinase expression and activity
have been observed in various cancer types. It was also reported to mediate tumorigenic activity,
which is probably linked to its ability to control cell adhesion and migration, as well as to influence
cell-survival pathways [165].
By constructing PPI networks, connections between pathogenic proteins were visualized.
Screening of such genes and clusters from the network could help to confirm the essential genes
that are involved in the pathogenesis of PrCa. Among these, TTN is strongly correlated with an
emerging biomarker based on tumor mutational burden [166, 167]. While most mutations on this
gene are likely to be passenger mutations, such abundant mutations in tumor tissues still encourage
one to speculate its role in cancer development. TP53 and ATM are well-established driver genes
for PrCa while TRRAP is the driver for other cancers [120]. Among the 15 non-LPC pathogenic
genes with high degrees of connectivity (≥ 4) with LPC genes in Table 4.5, CHD4, RYBP, NKX3-
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1 and CSMD3 have either direct or indirect suppressive roles in PrCa [108,126,129,137]. Most
others are involved in the progression of other cancers as shown in the References column of Table
4.5. How these genes affect cancer development is not yet understood, making them intriguing
candidates for further investigation.
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Chapter 6 Conclusions and future work
In this research, we have proposed a novel method to integrate functional effect predictions
with frequency-based analysis of nsGSV and select pathogenic genes according to the cumulative
scores of GSVs in the gene. After enrichment analyses were performed on the selected top
pathogenic genes, their associations with known PrCa genes were revealed by a PPI network. This
workflow is incorporated into a new version of the web-based OncoMiner pipeline, which can be
publicly accessible by the scientific community.
When our method was applied to PrCa data, we not only identified a good number of genes
that are well-known to drive PrCa but also uncovered several novel genes with strong association
with PrCa based on a combined assessment of their general functional effects by FATHMM and
PROVEAN, observed occurrence frequencies in this dataset, and protein interactions with wellknown PrCa-related genes. While further studies on the specific functions of these genes and how
they participate in cancer formation and development are necessary in order to provide solid
evidence of their functional roles, they could be promising candidates to serve as biomarkers for
the diagnosis of PrCa.
It should be noted that the prediction results from FATHMM and PROVEAN play
important roles in the selection of high-scoring genes. As these types of functional effect prediction
tools increase in availability and quality, they can be incorporated to our current scoring scheme
to further improve the reliability of our proposed computational approach and reduce the work of
laboratory validation. Moreover, we expect that our method would not only work on single
nucleotide substitution GSVs, but can be easily extended to handle other small-scale mutations
including indels. These could be good follow-up implementation projects that will make useful
contributions and enhance the flexibility and versatility of the OncoMiner pipeline.
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Appendix
A File conversion and variant annotation
import
import
import
import
import

vcf
csv
time
timeit
gc

def writecsv(inputvcf):
chr_start = time.time()
vcf_reader = vcf.Reader(open(inputvcf,'r'))
outfile_name=[]
col_name=[['var_index','chrom','left','right','ref_seq','var_seq1','var_se
q2','count1','count2','var_score','gene_name','where_in_transcript']]#,'ID
''genotype',
index=[]
chrom=[]
left=[]
right=[]
ref=[]
alt=[]
alt2=[]
tags=[]
names=locals()
sample_names=[]
sample_temps=[]
base_pool=[['A'],['C'],['G'],['T']]
record=next(vcf_reader)
#dynamically names output file for each sample
for i in range(0,len(record.samples)):
names['%s' %''.join([char for char in record.samples[i].sample if
char.isalnum()])]=[]
names['%s' %''.join([char for char in
record.samples[i].sample.lower() if char.isalnum()])]=[]
names['count1%s' %i]=[]
names['count2%s' %i]=[]
#names['GT%s' %i]=[] ################################
new
sample_temps.append(''.join([char for char in
record.samples[i].sample if char.isalnum()]))
sample_names.append(''.join([char for char in
record.samples[i].sample.lower() if char.isalnum()]))
vcf_reader = vcf.Reader(open(inputvcf,'r'))
for record in vcf_reader:
chrom.append(record.CHROM.split())
right.append(record.POS)
left.append(str(record.POS).split())
ref.append(record.REF.split())
alt.append(record.ALT)
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tags.append(record.FORMAT.split(':'))
for j in range(0,len(record.samples)):
eval(sample_temps[j]).append(record.samples[j])
for m in range(0,len(tags)):
for k in range(0,len(record.samples)):
names['temp%s' %k]=[]
for n in range(0,len(tags[0])):
if(tags[0][n] not in tags[m][n]):
for j in range(0,len(record.samples)):
eval('temp'+str(j)).append(None)
tags[m].insert(n,tags[0][n])
else:
for j in range(0,len(record.samples)):
eval('temp'+str(j)).append(eval(sample_temps[j])[m][tags[0][n]])
for j in range(0,len(record.samples)):
eval(sample_names[j]).append(eval('temp'+str(j)))
def get_index(input_list):
AD=-1
BCOUNT=-1
for j in range(0,len(input_list)):
if (input_list[j]=='AD'):
AD=j
return AD
elif (input_list[j]=='BCOUNT'):
BCOUNT=j
return BCOUNT
else:
continue
return
index_count=get_index(tags[0])
if (len(chrom)==len(left)==len(ref)==len(alt)):
for j in range(0,len(record.samples)):
names['list0%s' %j]=[[]]*len(chrom)
names['temp%s' %j]=[[]]*len(chrom)
index=[num for num in range(1,(len(chrom)+1))]
score=[['28']]*len(chrom)
alt2=[['']]*len(chrom)
for i in range(0,len(chrom)):
if(len(alt[i])>1):
alt2[i]=[str(alt[i][1])]
alt[i]=[str(alt[i][0])]
else:
if(ref[i][0]<str(alt[i][0])):
alt2[i]=[str(alt[i][0])]
alt[i]=ref[i]
else:
alt2[i]=ref[i]
alt[i]=[str(alt[i][0])]
index[i]=[str(index[i])]
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right[i]=[str(right[i]+len(ref[i]))]
#for j in range(0,len(record.samples)):
##############################################
This is new
#
eval('GT'+str(j)).append([",".join(eval(sample_names[j])[i][0].split('/'))
])
if('BCOUNT' in tags[0]):
pos1=base_pool.index(alt[i])
pos2=base_pool.index(alt2[i])
for k in range(0,len(record.samples)):
eval('count1'+str(k)).append([eval(sample_names[k])[i][index_count][pos1]]
)
eval('count2'+str(k)).append([eval(sample_names[k])[i][index_count][pos2]]
)
elif('AD' in tags[0]):
if(alt[i]==ref[i]):
for k in range(0,len(record.samples)):
eval('count1'+str(k)).append([eval(sample_names[k])[i][index_count][0]])
eval('count2'+str(k)).append([eval(sample_names[k])[i][index_count][1]])
elif(alt2[i]==ref[i]):
for k in range(0,len(record.samples)):
eval('count1'+str(k)).append([eval(sample_names[k])[i][index_count][1]])
eval('count2'+str(k)).append([eval(sample_names[k])[i][index_count][0]])
else:
for k in range(0,len(record.samples)):
eval('count1'+str(k)).append([eval(sample_names[k])[i][index_count][0]])
eval('count2'+str(k)).append([eval(sample_names[k])[i][index_count][1:len(
eval(sample_names[k])[i][index_count])]])
else:
break
for j in range(0,len(record.samples)):
eval('list0'+str(j))[i]= index[i]+chrom[i]+
left[i]+ right[i]+ ref[i]+
alt[i]+alt2[i]+eval('count1'+str(j))[i]+eval('count2'+str(j))[i]+score[i]#
+normal[i]+ID[i]+eval('GT'+str(j))[i]
#eval('temp'+str(j))[i]=eval('list0'+str(j))[i]
eval('temp'+str(j))[i]= index[i]+chrom[i]+
left[i]+ right[i]+ ref[i]+
alt[i]+alt2[i]+eval('count1'+str(j))[i]+eval('count2'+str(j))[i]+score[i]
for p in range(0,len(record.samples)):
for ele in eval('temp'+str(p)):
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if (type(ele[8])==int):
if ((ele[7]+ele[8])<=5 or ele[7]/(ele[7]+ele[8])<=0.05 or
ele[8]/(ele[7]+ele[8])<=0.05):
eval('list0'+str(p)).remove(ele)
else:
pos=eval('list0'+str(p)).index(ele)
eval('list0'+str(p)).insert(pos+1,ele)
if (ele[4]<ele[5]):
eval('list0'+str(p))[pos][8]=ele[8][0]
eval('list0'+str(p))[pos][5]=ele[4]
eval('list0'+str(p))[pos][6]=ele[5]
else:
eval('list0'+str(p))[pos][7]=ele[8][0]
eval('list0'+str(p))[pos][5]=ele[5]
eval('list0'+str(p))[pos][6]=ele[4]
eval('list0'+str(p))[pos][8]=ele[7]
if (ele[4]<ele[6]):
eval('list0'+str(p))[pos+1][8]=ele[8][1]
eval('list0'+str(p))[pos+1][5]=ele[4]
eval('list0'+str(p))[pos+1][6]=ele[6]
else:
eval('list0'+str(p))[pos+1][7]=ele[8][1]
eval('list0'+str(p))[pos+1][5]=ele[6]
eval('list0'+str(p))[pos+1][6]=ele[4]
eval('list0'+str(p))[pos+1][8]=ele[7]
if
((eval('list0'+str(p))[pos+1][7]+eval('list0'+str(p))[pos+1][8])<=5 or
eval('list0'+str(p))[pos+1][7]/(eval('list0'+str(p))[pos+1][7]+eval('list0
'+str(p))[pos+1][8])<=0.05
or
eval('list0'+str(p))[pos+1][8]/(eval('list0'+str(p))[pos+1][7]+eval('list0
'+str(p))[pos+1][7])<=0.05):
eval('list0'+str(p)).pop(pos+1)
if
((eval('list0'+str(p))[pos][7]+eval('list0'+str(p))[pos][8])<=5 or
eval('list0'+str(p))[pos][7]/(eval('list0'+str(p))[pos][7]+eval('list0'+st
r(p))[pos][8])<=0.05
or
eval('list0'+str(p))[pos][8]/(eval('list0'+str(p))[pos][7]+eval('list0'+st
r(p))[pos][7])<=0.05):
eval('list0'+str(p)).pop(pos)
index1=[num for num in range(1,(len(eval('list0'+str(p)))+1))]
for q in range(len(eval('list0'+str(p)))):
eval('list0'+str(p))[q][0]=index1[q]
for h in range(0,len(record.samples)):
names['file1%s' %h]=open(sample_names[h]+'.csv',"a",newline='')
outfile_name.append(sample_names[h]+'.csv')
with eval('file1'+str(h)):
writer=csv.writer(eval('file1'+str(h)))
writer.writerows(col_name)
writer.writerows(eval('list0'+str(h)))
for h in range(0,len(record.samples)):
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eval('file1'+str(h)).close()
end = time.time()-chr_start
del index
del chrom
del ref
del alt
del alt2
for key in list(locals()):
if (key.startswith('list0') or key.startswith('temp')):
del locals()[key]
del vcf_reader
gc.collect()
return outfile_name

from multiprocessing import Pool,Manager
import os
from math import fabs
import sys
from miscVar import AADict
import time
import csv
import gc
MAX_DIST = 5000
#function for processing vcf, returns dict
def vcf_func(vcffile,gtf,genome):
chr_start = time.time()
vcffile = open('%s'%(vcffile), 'r')
vcf = vcffile.readlines()
vcffile.close()
gtffile = gtf
f = open(gtffile,'r')
flat = f.readlines()
f.close()
seqfile=open(genome,'r')
next(seqfile)
sequence=seqfile.read().replace('\n','')
seqfile.close()
dictionary= {}
position = 0
chrom=''
#genestart = 0
#genestop = 0
start_time = time.time()
for l in range(0, len(vcf)): #line in vcf:
if vcf[l].startswith('chr'):
line = vcf[l].strip()
vl = line.split() #split on all white space
chrom=vl[0]
position = int(vl[1])
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ref=vl[3]
alt=vl[4]
gtfCounter = -1 #point to each line in gtf file
genestart = 0
genestop = 0
if position not in dictionary:
boo = 0
where = []
genename = []
change_type=[]
aachange=[]
counter=[]
strand_gene=[]
while boo == 0 and gtfCounter < len(flat):
if position >genestart and position <= genestop and
gtfCounter < (len(flat)-1): #GSV within gene
counter.append(gtfCounter)
strand_gene.append(flat[gtfCounter].split()[3])
#if (gtfCounter < (len(flat)-1)):
gtfCounter += 1
pgstop = genestop
genestart = int(flat[gtfCounter].split()[4])
#transcript start
genestop = int(flat[gtfCounter].split()[5])
#transcript end
elif position > genestop and gtfCounter < (len(flat)-1):
#Moves to the next gene
gtfCounter += 1
pgstop = genestop #prev gene stop
genestart = int(flat[gtfCounter].split()[4])
#transcript start
genestop = int(flat[gtfCounter].split()[5])
#transcript end
elif position < genestart and position > pgstop:
boo = 1
else:
boo = 1
if len(strand_gene)==0:
strand_gene.append('')
strand = flat[gtfCounter].split()[3] #ref strand direction
run_time = time.time() - start_time
if len(counter)==0:
if gtfCounter == len(flat)-1 and position > genestop:
if (position - genestop) > MAX_DIST: #if variant
position is far from the end of transcript
genename.append('NoName')
where.append('Not close to gene')
change_type.append('')
aachange.append('')
else:
genename.append(flat[gtfCounter].split()[0])
#else whether close to 3' or 5'
if strand == '-':
where.append('5\' untranscribed')
change_type.append('')
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aachange.append('')
else:
where.append('3\' untranscribed')
change_type.append('')
aachange.append('')
elif position < genestart and position > pgstop:
# check if closer to start or end of the one before
or current
diff1 = fabs(position-genestart) #current
diff2 = fabs(position-pgstop) #previous
if diff1 <= diff2 and diff1 <= MAX_DIST: #if closer to
current "new " gene and within cutoff distance
genename.append(flat[gtfCounter].split()[0])
if strand == '-':
where.append('3\' untranscribed')
change_type.append('')
aachange.append('')
else:
where.append('5\' untranscribed')
change_type.append('')
aachange.append('')
elif diff2 <= MAX_DIST: #if closer to prev gene and
within cutoff distance
genename.append(flat[gtfCounter-1].split()[0])
strand = flat[gtfCounter-1].split()[3]
if strand == '-':
where.append('5\' untranscribed')
change_type.append('')
aachange.append('')
else:
where.append('3\' untranscribed')
change_type.append('')
aachange.append('')
else:
genename.append('NoName')
where.append('Not close to gene')
change_type.append('')
aachange.append('')
else:
continue
else:
for i in range(len(counter)):
genename.append(flat[counter[i]].split()[0])
#tr_start = int(flat[counter[i]].split()[4])
#transcript start; check
#tr_end = int(flat[counter[i]].split()[5])
#transcript end; check
cd_start=int(flat[counter[i]].split()[6]) #CDS start
cd_end=int(flat[counter[i]].split()[7]) #CDS end
ex_starts = []
ex_ends=[]
x=0
tmp = 'Unknown'
ex_starts = [int(i) for i in flat[counter[i]].split()[2].split(',')[0:-1]]
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ex_ends = [int(i) for i in flat[counter[i]].split()[1].split(',')[0:-1]]
while tmp == 'Unknown' and x < len(ex_starts):
if position > ex_starts[x] and position <=
ex_ends[x]: #if position in exon
tmp = 'Exon'
elif position <= ex_starts[x]:
tmp = 'Intron'
else:
x+=1
if tmp == 'Intron' or tmp=='Unknown':
where.append('Intron')
change_type.append('')
aachange.append('')
#see if position is in translated region:
elif tmp == 'Exon':
if position > cd_start and position <= cd_end:
tmp = 'Translated'
else: #not translated
tmp = 'Not translated'
if tmp == 'Not translated':
if cd_start == cd_end: #ncRNAs
where.append('Not translated, ncRNA')
change_type.append('')
aachange.append('')
else: #utrs
if position <= cd_start:
if strand_gene[i] == '-':
where.append('Not translated,3\'
utr')
change_type.append('')
aachange.append('')
else:
where.append('Not translated,5\'
utr')
change_type.append('')
aachange.append('')
else:
if strand_gene[i] == '-':
where.append('Not translated,5\'
utr')
change_type.append('')
aachange.append('')
else:
where.append('Not translated,3\'
utr')
change_type.append('')
aachange.append('')
elif tmp == 'Translated':
where.append('CDS')
ref_codon=''
var_codon=''
aalength=0
m=0
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toRev=0
#m = (position - cd_start) % 3
if strand_gene[i]=="+":
ex=0
#pre_ex=0
while ex != (len(ex_ends)-1) and
position > ex_ends[ex]:
if cd_start > ex_ends[ex]:
ex+=1
elif cd_start > ex_starts[ex] and
cd_start < ex_ends[ex] and position > ex_ends[ex]:
#pre_ex=ex
m = ((ex_ends[ex] cd_start )+m)%3
aalength+=(ex_ends[ex] cd_start)
ex+=1
else:
# pre_ex=ex
m = ((ex_ends[ex]ex_starts[ex])+m)%3
aalength+=(ex_ends[ex] ex_starts[ex])
ex+=1
#print("ex is %d" %ex)
if cd_start > ex_starts[ex]:
m=(position-cd_start -1+m )%3
aalength+=(position-cd_start)
else:
m=(position-ex_starts[ex] -1+m)%3
aalength+=(position-ex_starts[ex])
if aalength%3==0:
aapos=aalength//3
else:
aapos=aalength//3 + 1
#if len(ref)==len(alt)and
position<len(sequence)-2:
if m==0 :
if len(ref)==1:
ref_codon=ref+sequence[position]+sequence[position+1]
var_codon=alt+sequence[position]+sequence[position+1]
elif len(ref)==2:
ref_codon=ref+sequence[position]
var_codon=alt+sequence[position]
else:
ref_codon=ref
var_codon=alt
elif m==1:
if len(ref)==1:
ref_codon = sequence[position2]+ref+ sequence[position]
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var_codon = sequence[position 2]+alt+sequence[position]
elif len(ref)==2:
ref_codon = sequence[position2]+ref
var_codon = sequence[position 2]+alt
else:
ref_codon = sequence[position2]+ref[0:2]
var_codon = sequence[position 2]+alt[0:2]
else:
if len(ref)==1:
ref_codon = sequence[position3]+sequence[position-2]+ref
var_codon = sequence[position3]+sequence[position-2]+alt
elif len(ref)==2:
ref_codon =
ref[1]+sequence[position]+sequence[position+1]
var_codon =
alt[1]+sequence[position]+sequence[position+1]
else:
ref_codon =
ref[1:]+sequence[position]
var_codon =
alt[1:]+sequence[position]
else:
ex = len(ex_starts)-1
while ex != 0 and position <
int(ex_starts[ex]):
if cd_end < ex_starts[ex]:
ex-=1
elif cd_end < ex_ends[ex] and cd_end >
ex_starts[ex] and position < ex_starts[ex]:
m = ((cd_end ex_starts[ex])+m)%3
aalength=(cd_end-ex_starts[ex])
ex-=1
else:
m = ((ex_ends[ex]ex_starts[ex])+m)%3
aalength+=(ex_ends[ex]ex_starts[ex])
ex-=1
if cd_end > ex_ends[ex]:
m=(ex_ends[ex] - position +m)%3
aalength+=(ex_ends[ex]-position)
else:
m=(cd_end - position + m)%3
aalength+=(cd_end-position)
if aalength%3==0:
aapos=aalength//3
else:
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aapos=aalength//3 + 1
toRev=1
if m==0 :
if len(ref)==1:
ref_codon=ref+sequence[position2]+sequence[position-3]
var_codon=alt+sequence[position2]+sequence[position-3]
elif len(ref)==2:
ref_codon=ref+sequence[position2]
var_codon=alt+sequence[position2]
else:
ref_codon=ref
var_codon=alt
elif m==1:
if len(ref)==1:
ref_codon =
sequence[position]+ref+ sequence[position-2]
var_codon =
sequence[position]+alt+sequence[position-2]
elif len(ref)==1:
ref_codon =
sequence[position]+ref
var_codon =
sequence[position]+alt
else:
ref_codon =
sequence[position]+ref[0:2]
var_codon =
sequence[position]+alt[0:2]
else:
if len(ref)==1:
ref_codon =
sequence[position+1]+sequence[position]+ref
var_codon =
sequence[position+1]+sequence[position]+alt
elif len(ref)==1:
ref_codon=ref[1]+sequence[position-2]+sequence[position-3]
var_codon=alt[1]+sequence[position-2]+sequence[position-3]
else:
ref_codon=ref[1:]+sequence[position-2]
var_codon=alt[1:]+sequence[position-2]
ref_codon=ref_codon.upper()
var_codon=var_codon.upper()
if toRev==1:
intab = "ATCG"
outtab = "TAGC"
trantab = str.maketrans(intab, outtab)
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var_codon = var_codon.translate(trantab)
ref_codon = ref_codon.translate(trantab)
var_codon = var_codon[0:3]
ref_codon = ref_codon[0:3]
ref_aa=''
var_aa=''
if var_codon in AADict:
var_aa = AADict[var_codon] #translate
if ref_codon in AADict:
ref_aa = AADict[ref_codon]
aachange.append(ref_aa+str(aapos)+var_aa)
if var_aa == ref_aa:
change_type.append('Synonymous')
else:
change_type.append('Non-synonymous')
else: #To make sure to fill change type in on the
ignored ones.
where.append('Ignore')
change_type.append('')
else:
where.append('Ignore')
change_type.append('')
dictionary[position]=[chrom,genename,where,change_type,aachange]
strand_gene for SIFT format
chr_end = time.time() - chr_start
del vcffile
del seqfile
gc.collect()
return dictionary

AADict = {"TTT":"F", "TTC":"F", "TTA":"L", "TTG":"L",
"TCT":"S", "TCC":"S", "TCA":"S", "TCG":"S",
"TAT":"Y", "TAC":"Y", "TAA":"*", "TAG":"*",
"TGT":"C", "TGC":"C", "TGA":"*", "TGG":"W",
"CTT":"L", "CTC":"L", "CTA":"L", "CTG":"L",
"CCT":"P", "CCC":"P", "CCA":"P", "CCG":"P",
"CAT":"H", "CAC":"H", "CAA":"Q", "CAG":"Q",
"CGT":"R", "CGC":"R", "CGA":"R", "CGG":"R",
"ATT":"I", "ATC":"I", "ATA":"I", "ATG":"M",
"ACT":"T", "ACC":"T", "ACA":"T", "ACG":"T",
"AAT":"N", "AAC":"N", "AAA":"K", "AAG":"K",
"AGT":"S", "AGC":"S", "AGA":"R", "AGG":"R",
"GTT":"V", "GTC":"V", "GTA":"V", "GTG":"V",
"GCT":"A", "GCC":"A", "GCA":"A", "GCG":"A",
"GAT":"D", "GAC":"D", "GAA":"E", "GAG":"E",
"GGT":"G", "GGC":"G", "GGA":"G", "GGG":"G",}
from parse_VCF import vcf_func
from VCF2CSV import writecsv
#from functools import partial
import csv
import vcf
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#include

import gc
import time
#import sys
import os
import xlwt
from xlutils.copy import copy
from xlrd import open_workbook
import multiprocessing
import argparse
#import resource
#Function combines all information and writes an OMI file
def writeOMI(infile,outfile,newfile):
start=time.time()
f1=open(outfile,'r')
rows=csv.reader(f1)
f2=open(newfile,'a',newline='')
writer=csv.writer(f2)
for row in rows:
for key in infile:
if (row[1]==infile[key][0] and row[2]==str(key)):
row.append(infile[key][1])
row.append(infile[key][2])
row.append(infile[key][3])
row.append(infile[key][4])
writer.writerow(row)
break
f1.close()
f2.close()
end=time.time()-start
del rows
gc.collect()
#Function that splits VCF file by chromosome for parallel processing
def splitvcf(vcffile):
start=time.time()
for i in range(1,23):
vcf_reader = vcf.Reader(open('%s' %(vcffile), 'r'))
outvcf=open('chr'+str(i)+'.vcf','w')#names['chr%s' %i]=[]
my_out=vcf.Writer(outvcf,vcf_reader)
for record in vcf_reader:
if (record.CHROM== 'chr'+str(i)):
my_out.write_record(record)
outvcf.close()
vcf_reader = vcf.Reader(open('%s' %(vcffile), 'r'))
outvcf1=open('chrX.vcf','w')
outvcf2=open('chrY.vcf','w')
my_out1=vcf.Writer(outvcf1,vcf_reader)
my_out2=vcf.Writer(outvcf2,vcf_reader)
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for record in vcf_reader:
if (record.CHROM== 'chrX'):
my_out1.write_record(record)
elif(record.CHROM== 'chrY'):
my_out2.write_record(record)
else:
continue
outvcf1.close()
outvcf2.close()
end=time.time()-start
del vcf_reader
gc.collect()
print('Time for generating vcf files:'+str(round(end))+'s')
return end
#Function that splits reference file by chromosome for parallel processing
def splitgtf(gtfdir):
start=time.time()
filegtf=open(gtfdir,'r')
flat=filegtf.readlines()
filegtf.close()
resultx=[]
resulty=[]
for i in range(1,23):
myout=open('chr'+str(i)+'_ref.txt','a')
result=[]
for line in flat:
if (line.split()[2]== 'chr'+str(i)):
result.append(line)
else:
continue
result=sorted(result, key=lambda x:int(x.split()[4]))
myout.writelines(result)
myout.close()
for line in flat:
if (line.split()[2]== 'chrX'):
resultx.append(line)
elif (line.split()[2]== 'chrY'):
resulty.append(line)
else:
continue
myoutx=open('chrX_ref.txt','a')
myouty=open('chrY_ref.txt','a')
resultx.sort()
resulty.sort()
myoutx.writelines(resultx)
myouty.writelines(resulty)
myoutx.close()
myouty.close()
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end=time.time()
del flat
del result
del resultx
del resulty
gc.collect()
print('Time for generating gtf files:'+str(round(end-start))+'s')
#Function that counts total number of variants, chromosomes and variants
per chromosome
def count_chrom(vcfdir):
vcffile=open('%s'%(vcfdir), 'r')
vcfall = vcffile.readlines()
chrom=[]
var_chr=[]
var_total=0
count=0
chrpool=['chrX','chrY']
for i in range(1,23):
chrpool.insert(i-1,'chr'+str(i))
for k in range(len(vcfall)):
line = vcfall[k].strip()
vl = line.split()
if(vl[0] in chrpool):
var_total+=1
if(vl[0] not in chrom):
chrom.append(vl[0])
var_chr.append(count)
count=1
else:
count+=1
var_chr.append(count)
del var_chr[0]
info=[chrom,var_chr,var_total]
vcffile.close()
del vcfall
del chrpool
gc.collect()
return info
if __name__=='__main__':
#vcfdir = input("vcf directory:")
#outdir = input("output directory:")
#gtfdir = input("gtf file:")
#cores = int(input("number of cores:"))
parser = argparse.ArgumentParser(description='Process VCF files to
generate OMI files')
parser.add_argument('-i', '--input_dir', metavar="DIRNAME",
dest='vcf_dir', required=True, help='Required: Input directory for all VCF
files.')
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parser.add_argument('-o', '--out_dir', metavar="DIRNAME",
dest='outdir', required=True, help='Required: Name of output directory to
store result files.')
parser.add_argument('-f', '--ref_flat', metavar="REFFLAT",
dest='ref_flat', required=True, help='Required: Reference genomic field
used to identify gene region,including path.')
parser.add_argument('-c', '--num_cores', metavar="NUMCORES",
dest='cores', type=int,default=3)
args = parser.parse_args()
vcfdir = args.vcf_dir
outdir = args.outdir
cores = args.cores
gtfdir = args.ref_flat
vcfs=os.listdir(vcfdir)
vcfs=[value for value in vcfs if value.endswith('.vcf')] #remove non-vcf
files under vcfdir
(refpath, gtfname) = os.path.split(gtfdir)
########## create the excel file to record runtimes if file does not exist
if(not os.path.exists('runtime.xls')):
workbook=xlwt.Workbook()
sheet1=workbook.add_sheet('sheet1',cell_overwrite_ok=True)
colname=['filename','Size','# GSVs','# chroms','# of samples']
for i in range(len(colname)):
sheet1.write(0,i,colname[i])
workbook.save('runtime.xls')
########## deal with each file
for file in vcfs:
#st_mem=resource.getrusage(resource.RUSAGE_SELF).ru_maxrss/1024
#memory usage at the beginning
starting = time.time()
time0=splitvcf(vcfdir+'/'+file)
splitgtf(gtfdir)
info=count_chrom(vcfdir+'/'+file)
(filename,extension)=os.path.splitext(file)
filesize=os.path.getsize(vcfdir+'/'+file)/(1024*1024)
if ('chrM' in info[0]):
info[0].remove('chrM')
vcf_by_chrom=[b+'.vcf' for b in info[0]]
time1=time.time()
######## create multiprocessing pool for copying information
pool=multiprocessing.Pool(processes=cores,maxtasksperchild=1)
pool_list1=[]
pool_list1=[pool.apply_async(writecsv,(vcf_by_chrom[i],)) for i in
range(len(info[0]))]
result1=[c.get() for c in pool_list1]
csv_name=result1[0]
pool.close()
pool.join()
time2=time.time()-time1
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print("Time for writing all csv:%.2f seconds" %(time2))
######## create final OMI files and write the header
for i in range(0,len(csv_name)):
f1=open(csv_name[i],'r')
header=f1.readline().strip('\n')
header1=header.split(',')
#header1.append('gene_name')
header1.append('change_type1')
header1.append('AAchange\n')
header1=",".join(header1)
f2=open(outdir+filename+'_'+csv_name[i],'a')
f2.write(header1)
f1.close()
f2.close()
#cores=multiprocessing.cpu_count()-1
pool=multiprocessing.Pool(processes=cores,maxtasksperchild=1)
######## prepare lists containing names of all reference files
ref=[b+'_ref.txt' for b in info[0]]
genome=[refpath+'/'+'genome_'+b+'.fa' for b in info[0]]
pool_list=[]
######## create multiprocessing pool for parsing
time3=time.time()
pool_list=[pool.apply_async(vcf_func,(vcf_by_chrom[i],ref[i],genome[i],))
for i in range(len(info[0]))]
result2=[c.get() for c in pool_list]
time4=time.time()-time3
print("Time for parsing whole vcf: %.2f seconds" %(time4))
time5=time.time()
if (len(csv_name) < cores):
for j in range(0,len(csv_name)):
pool_list=[pool.apply_async(writeOMI,(result2[i],csv_name[j],outdir+filena
me+'_'+csv_name[j],)) for i in range(len(info[0]))]
else:
result=result2[0].copy()
for j in range(1,len(result2)):
result.update(result2[j])
pool_list=[pool.apply_async(writeOMI,(result,csv_name[k],outdir+filename+'
_'+csv_name[k],)) for k in range(len(csv_name))]
pool.close()
pool.join()
time6=time.time()-time5
print("Time for writing all OMI: %.3f reconds" %(time6))
######## delete intermediate files
chrpool=['chrX','chrY']
for i in range(1,23):
chrpool.insert(i-1,'chr'+str(i))
for i in chrpool:
os.remove(i+'_ref.txt')
for k in chrpool:
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os.remove(k+'.vcf')
for j in csv_name:
os.remove(j)
#en_mem=resource.getrusage(resource.RUSAGE_SELF).ru_maxrss/1024#maximum
memory usage during the process
times=time.time()-starting
######## delete intermediate variables to release memory
del result1
del result2
del pool_list
del pool_list1
gc.collect()
######## record runtime information to excel file
rexcel=open_workbook('runtime.xls')
filelist=rexcel.sheet_by_name('sheet1').col_values(0)
header=rexcel.sheet_by_name('sheet1').row_values(0)
rows=rexcel.sheets()[0].nrows
excel=copy(rexcel)
table=excel.get_sheet(0)
#if filename already exists, append runtime information
if(filename in filelist):
file_index=filelist.index(filename)
if (cores in header):
core_index=header.index(cores)
table.write(file_index,core_index,times)
table.write(file_index,core_index+1,time0)
table.write(file_index,core_index+2,time2)
table.write(file_index,core_index+3,time4)
table.write(file_index,core_index+4,time6)
else:
table.write(0,len(header),cores)
table.write(0,len(header)+1,'generating vcf')
table.write(0,len(header)+2,'copy csv')
table.write(0,len(header)+3,'parsing')
table.write(0,len(header)+4,'write OMI')
table.write(file_index,len(header),times)
table.write(file_index,len(header)+1,time0)
table.write(file_index,len(header)+2,time2)
table.write(file_index,len(header)+3,time4)
table.write(file_index,len(header)+4,time6)
#if file does not exist, first write file information then runtime
else:
new_row=[filename,filesize,info[2],len(info[0]),len(csv_name)]
for i in range(len(new_row)):
table.write(rows,i,new_row[i])
if (cores in header):
core_index=header.index(cores)
table.write(rows,core_index,times)
table.write(rows,core_index+1,time0)
table.write(rows,core_index+2,time2)
table.write(rows,core_index+3,time4)
table.write(rows,core_index+4,time6)
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else:
table.write(0,len(header),cores)
table.write(0,len(header)+1,'splitvcf')
table.write(0,len(header)+2,'copy csv')
table.write(0,len(header)+3,'parsing')
table.write(0,len(header)+4,'write OMI')
table.write(rows,len(header),times)
table.write(rows,len(header)+1,time0)
table.write(rows,len(header)+2,time2)
table.write(rows,len(header)+3,time4)
table.write(rows,len(header)+4,time6)
excel.save('runtime.xls')
######## print out filename and total time used
print('Time elapsed:'+str(round(times,2))+' seconds')
print('Number of cores used:%d' %(cores))
print('VCF filename:%s' %(file))
#print(st_mem)
#print(en_mem)
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B Subject counts
import
import
import
import

numpy as np
os
pandas as pd
argparse

def subject_count(tumordir,normaldir,outdir):
#tumordir="D:\\Personal
materials\\PhD\\Oncominer\\Data\\PRODOMI\\OMI_PROD"
#normaldir="D:\\Personal
materials\\PhD\\Oncominer\\Data\\PRODOMI\\OMI_NORMAL"
tumors=os.listdir(tumordir)
normals=os.listdir(normaldir)
tumor=[value for value in tumors if value.endswith('tumor.csv')]
normal=[value for value in normals if value.endswith('normal.csv')]
tumorname=[value.split("_")[0] for value in tumor]
normalname=[value.split("_")[0] for value in normal]
del tumors,normals,tumor,normal
tumorvar=[]
normalvar=[]
commonvar=[]
counttumor=[]
countnormal=[]
countcommon=[]
numtum=0
numnor=0
numcom=0
if(normalname==tumorname):
disease_var=pd.DataFrame()
normal_var=pd.DataFrame()
common_var=pd.DataFrame()
for name in tumorname:
tf=pd.read_csv(tumordir+name+"_tumor.csv")
nf=pd.read_csv(normaldir+name+"_normal.csv")
norepeat_tf = tf.drop_duplicates(subset=['chrom',
'left','right','ref_seq','var_seq1',
'var_seq2'],
keep='first')
norepeat_nf = nf.drop_duplicates(subset=['chrom',
'left','right','ref_seq','var_seq1',
'var_seq2'],
keep='first')
tidx=[]
nidx=[]
for i in range(norepeat_tf.shape[0]):
for j in range(norepeat_nf.shape[0]):
if (norepeat_tf.iloc[i,1:7].values.tolist() ==
norepeat_nf.iloc[j,1:7].values.tolist()):

94

tidx.append(i)
nidx.append(j)
break
a=pd.DataFrame()
norepeat_tf=a.append(norepeat_tf,ignore_index=True)
norepeat_nf=a.append(norepeat_nf,ignore_index=True)
common=a.append(norepeat_tf.loc[tidx],ignore_index=True)
tempcom=a.append(norepeat_tf.loc[tidx],ignore_index=True)
norepeat_tf=norepeat_tf.drop(tidx,axis=0)
norepeat_nf=norepeat_nf.drop(nidx,axis=0)
temptf=a.append(norepeat_tf,ignore_index=True)
tempnf=a.append(norepeat_nf,ignore_index=True)
for j in range(common.shape[0]):
if (list(common.iloc[j,1:7]) in commonvar):
countcommon[commonvar.index(list(common.iloc[j,1:7]))]+=1
tempcom=tempcom.drop(j,axis=0)
else:
commonvar.append(list(common.iloc[j,1:7]))
countcommon.append(1)
numcom=numcom+tempcom.shape[0]
common_var=common_var.append(tempcom,ignore_index=True)
for j in range(norepeat_tf.shape[0]):
if (list(norepeat_tf.iloc[j,1:7]) in tumorvar):
counttumor[tumorvar.index(list(norepeat_tf.iloc[j,1:7]))]+=1
temptf=temptf.drop(j,axis=0)
else:
tumorvar.append(list(norepeat_tf.iloc[j,1:7]))
counttumor.append(1)
numtum=numtum+temptf.shape[0]
disease_var=disease_var.append(temptf,ignore_index=True)
for j in range(norepeat_nf.shape[0]):
if (list(norepeat_nf.iloc[j,1:7]) in normalvar):
countnormal[normalvar.index(list(norepeat_nf.iloc[j,1:7]))]+=1
tempnf=tempnf.drop(j,axis=0)
else:
normalvar.append(list(norepeat_nf.iloc[j,1:7]))
countnormal.append(1)
numnor=numnor+tempnf.shape[0]
normal_var=normal_var.append(tempnf,ignore_index=True)
### keep count in each group
disease_var.insert(disease_var.shape[1],"count",counttumor)
normal_var.insert(normal_var.shape[1],"count",countnormal)
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common_var.insert(common_var.shape[1],"count",countcommon)
transcript=disease_var.append(normal_var)
transcript=transcript.append(common_var)
transcript=transcript.drop_duplicates(subset=['chrom',
'left','right','ref_seq','var_seq1',
'var_seq2'],
keep='first')
t0n0=[0]*transcript.shape[0]
t0n1=[0]*transcript.shape[0]
t1n0=[0]*transcript.shape[0]
t1n1=[0]*transcript.shape[0]
for i in range(transcript.shape[0]):
var=transcript.iloc[i,0:7].tolist()
for name in tumorname:
tf=pd.read_csv(tumordir+name+"_tumor.csv")
nf=pd.read_csv(normaldir+name+"_normal.csv")
norepeat_tf = tf.drop_duplicates(subset=['chrom',
'left','right','ref_seq','var_seq1',
'var_seq2'],
keep='first')
norepeat_nf = nf.drop_duplicates(subset=['chrom',
'left','right','ref_seq','var_seq1',
'var_seq2'],
keep='first')
tfile=np.array(norepeat_tf.iloc[:,1:7]).tolist()
nfile=np.array(norepeat_nf.iloc[:,1:7]).tolist()
if var in tfile and var in nfile:
t1n1[i] += 1
elif var in tfile and var not in nfile:
t1n0[i] += 1
elif var not in tfile and var in nfile:
t0n1[i]+=1
else:
t0n0[i]+=1
transcript.insert(transcript.shape[1],"subt1n1",t1n1)
transcript.insert(transcript.shape[1],"subt1n0",t1n0)
transcript.insert(transcript.shape[1],"subt0n1",t0n1)
transcript.insert(transcript.shape[1],"subt0n0",t0n0)
alt=[]
for k in range(transcript.shape[0]):
if transcript.iloc[k,4]==transcript.iloc[k,5]:
alt.append(transcript.iloc[k,6])
else:
alt.append(transcript.iloc[k,5])
transcript.insert(5,'alt',alt)
transcript.drop(columns=['var_index','var_seq1',
'var_seq2'],inplace=True)
'''
transcript variants distribution combining tumor, normal and common
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'''
file_total_tumor=[0]*transcript.shape[0]
file_total_normal=[0]*transcript.shape[0]
for name in tumorname:
tf=pd.read_csv(tumordir+name+"_tumor.csv")
nf=pd.read_csv(normaldir+name+"_normal.csv")
norepeat_tf = tf.drop_duplicates(subset=['chrom',
'left','right','ref_seq','var_seq1',
'var_seq2'], keep='first')
norepeat_nf = nf.drop_duplicates(subset=['chrom',
'left','right','ref_seq','var_seq1',
'var_seq2'], keep='first')
alt=[]
for k in range(norepeat_tf.shape[0]):
if norepeat_tf.iloc[k,4]==norepeat_tf.iloc[k,5]:
alt.append(norepeat_tf.iloc[k,6])
else:
alt.append(norepeat_tf.iloc[k,5])
norepeat_tf.insert(5,'alt',alt)
norepeat_tf.drop(columns=['var_seq1', 'var_seq2'],inplace=True)
alt=[]
for k in range(norepeat_nf.shape[0]):
if norepeat_nf.iloc[k,4]==norepeat_nf.iloc[k,5]:
alt.append(norepeat_nf.iloc[k,6])
else:
alt.append(norepeat_nf.iloc[k,5])
norepeat_nf.insert(5,'alt',alt)
norepeat_nf.drop(columns=['var_seq1', 'var_seq2'],inplace=True)
per_file_tumor=[0]*transcript.shape[0]
per_file_normal=[0]*transcript.shape[0]
merge_tumor=pd.merge(transcript,norepeat_tf,on=['chrom', 'left',
'right', 'ref_seq', 'alt'],how='left')
include_tumor=merge_tumor[~merge_tumor['count1_y'].isnull()]
index_tumor=include_tumor._stat_axis.tolist()
for ele in index_tumor:
per_file_tumor[ele]=1
file_total_tumor[ele]+=1
merge_normal=pd.merge(transcript,norepeat_nf,on=['chrom', 'left',
'right', 'ref_seq', 'alt'],how='left')
include_normal=merge_normal[~merge_normal['count1_y'].isnull()]
index_normal=include_normal._stat_axis.tolist()
for ele in index_normal:
per_file_normal[ele]=1
file_total_normal[ele]+=1

transcript.insert(transcript.shape[1],name+'_tumor',per_file_tumor)
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transcript.insert(transcript.shape[1],name+'_normal',per_file_normal)
#return transcript
transcript.to_csv(outdir+"sub_count_dist.csv",index=False)
if __name__=='__main__':
#tumordir=input("directory of tumor OMI file:")
#normaldir=input("directory of normal OMI file:")
#outdir=input("directory of output file:")
parser = argparse.ArgumentParser(description='count subjects for each
variant')
parser.add_argument('-t', '--input_dir', metavar="TUMORDIR",
dest='tumor', required=True, help='Required: Directory to all tumor OMI
files.')
parser.add_argument('-o', '--out_dir', metavar="DIRNAME",
dest='outdir', required=True, help='Required: Name of output directory to
store result file.')
parser.add_argument('-n', '--input_dir', metavar="NORMALDIR",
dest='normal', required=True, help='Required: Directory to all normal OMI
files.')
args = parser.parse_args()
tumordir = args.tumor
normaldir = args.normal
outdir = args.outdir
subject_count(tumordir,normaldir,outdir)
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C Functional predictions
# -*- coding: utf-8 -*import os
import pandas as pd
import mechanicalsoup
from urllib.request import urlopen
from bs4 import BeautifulSoup
import time
import csv
import argparse
def fathmm(omifile,fatout,build='hg38',sleeptime=60):
omi = pd.read_csv(omifile)
directory,name=os.path.split(omifile)
name=name.split(".")[0]
del directory
temp=omi[['left', 'ref_seq']]
alt=[]
for i in range(omi.shape[0]):
if omi.iloc[i,5]==omi.iloc[i,6]:
alt.append(omi.iloc[i,7])
else:
alt.append(omi.iloc[i,6])
chrom=omi['chrom'].apply(lambda x : x[3:])
temp.insert(0,'chrom',chrom)
temp.insert(3,'alt',alt)
temp['left']=temp['left'].apply(lambda x:str(x))
temp=temp.drop_duplicates()
fathmm=temp.apply(lambda x:x['chrom']+','+ x['left']+','+
x['ref_seq']+','+ x['alt'],axis=1)
del temp,i,alt,chrom,omi
browser = mechanicalsoup.StatefulBrowser()
browser.open("http://fathmm.biocompute.org.uk/fathmm-xf/")
browser.get_url()
browser.get_current_page()
browser.select_form('form[name="myForm"]')
browser["batch"]='\n'.join(fathmm.tolist())
if build=='hg38':
browser["hg38"]="hg38"
response = browser.submit_selected()
time.sleep(sleeptime)
browser.get_url()
temp=response.text.split("session=")
session=temp[1].split("\'")[0]
resulturl="http://fathmm.biocompute.org.uk/fathmm-xf/cgibin/results.cgi?session="+session
#resultpage=urllib.request.urlopen(resulturl).read()
resultpage=urlopen(resulturl).read()
soup = BeautifulSoup(resultpage, 'html.parser')

99

table = soup.find('table', attrs={'class': 'table table-striped tablebordered'})
headings = [th.get_text() for th in table.find("tr").find_all("th")]
datasets = []
for row in table.find_all("tr")[1:]:
dataset = [td.get_text() for td in row.find_all("td")]
datasets.append(dataset)
output=open(fatout+name+"_fathmm.csv",'a',newline='')
writer=csv.writer(output)
writer.writerow(headings)
for ele in datasets:
writer.writerow(ele)
output.close()
return
if __name__=='__main__':
parser = argparse.ArgumentParser(description='prepare for FATHMM
submission and parse results')
parser.add_argument('-i', '--input_file', metavar="FILENAME",
dest='omi', required=True, help='Required: Input OMI file.')
parser.add_argument('-o', '--output_dir', metavar="DIRNAME",
dest='outdir', required=True, help='Required: Name of output directory to
store results.')
parser.add_argument('-r', '--reference_build', metavar="ref_build",
dest='ref', default='hg38', help='Choose reference genome going to be
used')
parser.add_argument('-t', '--runtime', metavar="runtime", dest='time',
type=int, default=60)
args = parser.parse_args()
omifile = args.omi
outdir = args.outdir
build=args.ref
sleeptime=args.time
fathmm(omifile,outdir,build,sleeptime)

# -*- coding: utf-8 -*import re
from miscVar import AADict
MAX_DIST = 5000
import bisect
import pandas as pd
import os
import argparse
def get_same_element_index(ob_list, word):
return [i for (i, v) in enumerate(ob_list) if v == word]
intab = "ATCG"
outtab = "TAGC"
trantab = str.maketrans(intab, outtab)
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def annotation(unify,build,flat):
dictionary= {}
position = 0
chrom=''
prechrom=0
flatpath,flatname=os.path.split(flat)
seqpath,seqname=os.path.split(build)
for l in range(unify.shape[0]): #line in vcf:
chrom=unify["chrom"][l]
position = unify["left"][l]
ref=unify['ref_seq'][l]
alt=unify['alt'][l]
gtfCounter = -1
genestart = 0
genestop = 0
boo = 0
where = []
genename = []
change_type=[]
counter=[]
strand_gene=[]
aavar=[]
dnasequence=[]
codon_pos=[]
ref_trip=[]
var_trip=[]
if chrom != prechrom:
f = open(flatpath+str(chrom)+flatname,'r')
flat = f.readlines()
f.close()
seqfile=open(seqpath+"_"+str(chrom)+".fa",'r')
next(seqfile)
sequence=seqfile.read().replace('\n','')
seqfile.close()
prechrom=chrom
while boo == 0 and gtfCounter < len(flat):
if position >= genestart and position <= genestop and
gtfCounter < (len(flat)-1):
counter.append(gtfCounter)
strand_gene.append(flat[gtfCounter].split()[3])
gtfCounter += 1
pgstop = genestop
genestart = int(flat[gtfCounter].split()[4]) #transcript
start
genestop = int(flat[gtfCounter].split()[5]) #transcript
end
elif position > genestop and gtfCounter < (len(flat)-1):
gtfCounter += 1
pgstop = genestop #prev gene stop
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genestart = int(flat[gtfCounter].split()[4]) #transcript
start
genestop = int(flat[gtfCounter].split()[5]) #transcript
end
elif position < genestart and position > pgstop:
boo = 1
else:
boo = 1
if len(strand_gene)==0:
strand_gene.append('')
for i in range(len(counter)):
genename.append(flat[counter[i]].split()[0]+'_'+str(counter[i]))
cd_start=int(flat[counter[i]].split()[6]) #CDS start
cd_end=int(flat[counter[i]].split()[7]) #CDS end
ex_starts = []
ex_ends=[]
dnaseq=''
x=0
tmp = 'Unknown'
ex_starts = [int(i) for i in flat[counter[i]].split()[2].split(',')[0:-1]]
ex_ends = [int(i) for i in flat[counter[i]].split()[1].split(',')[0:-1]]
while tmp == 'Unknown' and x < len(ex_starts):
if position > ex_starts[x] and position <= ex_ends[x]: #if
position in exon
tmp = 'Exon'
elif position < ex_starts[x]:
tmp = 'Intron'
else:
x+=1
if tmp == 'Intron' or tmp=='Unknown':
where.append('Intron')
change_type.append('')
#see if position is in translated region:
elif tmp == 'Exon':
if position > cd_start and position <= cd_end:
tmp = 'Translated'
else: #not translated
tmp = 'Not translated'
if tmp == 'Not translated':
if cd_start == cd_end: #ncRNAs
where.append('Not translated, ncRNA')
change_type.append('')
else: #utrs
if position < cd_start:
if strand_gene[i] == '-':
where.append('Not translated,3\' utr')
change_type.append('')
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else:
where.append('Not translated,5\'
change_type.append('')
else:
if strand_gene[i] == '-':
where.append('Not translated,5\'
change_type.append('')
else:
where.append('Not translated,3\'
change_type.append('')
elif tmp == 'Translated':
where.append('CDS')
ref_codon=''
var_codon=''
m=0
toRev=0
aapos=0
aaseq=''
#m = (position - cd_start) % 3
if strand_gene[i]=="+":
ex=0
while ex != (len(ex_ends)-1) and position

utr')

utr')
utr')

>

ex_ends[ex]:
if cd_start > ex_ends[ex]:
ex+=1
elif cd_start > ex_starts[ex] and cd_start <
ex_ends[ex] and position > ex_ends[ex]:
m = ((ex_ends[ex] - cd_start)+m)%3
aapos+=(ex_ends[ex] - cd_start)
ex+=1
else:
m = ((ex_ends[ex]-ex_starts[ex])+m)%3
aapos+=(ex_ends[ex]-ex_starts[ex])
ex+=1
if cd_start > ex_starts[ex]:
m=(position-cd_start -1+m )%3
aapos+=(position-cd_start)
else:
m=(position-ex_starts[ex] -1+m)%3
aapos+=(position-ex_starts[ex])
if aapos%3==0:
pos=aapos//3
else:
pos=aapos//3 + 1
firstex=bisect.bisect(ex_starts, cd_start)-1
lastex=bisect.bisect(ex_ends,cd_end)
if lastex>=len(ex_ends):
lastex=len(ex_ends)-1
if ex_ends[firstex]>cd_start:
dnaseq =
dnaseq+sequence[cd_start:ex_ends[firstex]]
firstex+=1
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while firstex < lastex:
dnaseq=dnaseq+sequence[ex_starts[firstex]:ex_ends[firstex]]
firstex+=1
if cd_end > ex_starts[lastex]:
dnaseq=dnaseq+sequence[ex_starts[lastex]:cd_end]
if m==0 :
ref_codon=ref+sequence[position]+sequence[position+1]
var_codon=alt+sequence[position]+sequence[position+1]
codon_pos.append(1)
elif m==1:
ref_codon = sequence[position-2]+ref+
sequence[position]
var_codon = sequence[position 2]+alt+sequence[position]
codon_pos.append(2)
else:
ref_codon = sequence[position3]+sequence[position-2]+ref
var_codon = sequence[position3]+sequence[position-2]+alt
codon_pos.append(3)
else:
ex = len(ex_starts)-1
while ex != 0 and position < int(ex_starts[ex]):
if cd_end < ex_starts[ex]:
ex-=1
elif cd_end < ex_ends[ex] and cd_end >
ex_starts[ex] and position < ex_starts[ex]:
m = ((cd_end - ex_starts[ex] )+m)%3
aapos=(cd_end-ex_starts[ex])
ex-=1
else:
m = ((ex_ends[ex]-ex_starts[ex] )+m)%3
aapos+=(ex_ends[ex]-ex_starts[ex])
ex-=1
if cd_end > ex_ends[ex]:
m=(ex_ends[ex] - position + m)%3
aapos+=(ex_ends[ex]-position)
else:
m=(cd_end - position + m)%3
aapos+=(cd_end-position)
if aapos%3==0:
pos=aapos//3
else:
pos=aapos//3 + 1
firstex=bisect.bisect(ex_starts, cd_start)-1
lastex=bisect.bisect(ex_ends,cd_end)
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if lastex>=len(ex_ends):
lastex=len(ex_ends)-1
if ex_ends[firstex]>cd_start:
dnaseq =
dnaseq+sequence[cd_start:ex_ends[firstex]]
firstex+=1
while firstex < lastex:
dnaseq=dnaseq+sequence[ex_starts[firstex]:ex_ends[firstex]]
firstex+=1
if cd_end > ex_starts[lastex]:
dnaseq=dnaseq+sequence[ex_starts[lastex]:cd_end]
dnaseq=dnaseq[::-1]
toRev=1
if m==0 :
ref_codon=ref+sequence[position2]+sequence[position-3]
var_codon=alt+sequence[position2]+sequence[position-3]
codon_pos.append(1)
elif m==1:
ref_codon = sequence[position]+ref+
sequence[position-2]
var_codon =
sequence[position]+alt+sequence[position-2]
codon_pos.append(2)
else:
ref_codon =
sequence[position+1]+sequence[position]+ref
var_codon =
sequence[position+1]+sequence[position]+alt
codon_pos.append(3)
ref_codon=ref_codon.upper()
var_codon=var_codon.upper()
if toRev==1:
intab = "ATCG"
outtab = "TAGC"
trantab = str.maketrans(intab, outtab)
var_codon = var_codon.translate(trantab)
ref_codon = ref_codon.translate(trantab)
var_codon = var_codon[0:3]
ref_codon = ref_codon[0:3]
ref_aa=''
var_aa=''
if var_codon in AADict:
var_aa = AADict[var_codon] #translate
if ref_codon in AADict:
ref_aa = AADict[ref_codon]
if var_aa == ref_aa:
change_type.append('Synonymous')
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else:
change_type.append('Non-synonymous')
aavar.append(ref_aa+str(int(pos))+var_aa)
ref_trip.append(ref_codon)
var_trip.append(var_codon)
dnasequence.append(dnaseq)
else: #To make sure to fill change type in on the ignored
ones.
where.append('Ignore')
change_type.append('')
else:
where.append('Ignore')
change_type.append('')
dictionary[l]=[chrom,position,strand_gene,genename,where,change_type,dnase
quence]
return dictionary
if __name__=='__main__':
parser = argparse.ArgumentParser(description='prepare for PROVEAN
submission')
parser.add_argument('-i', '--input_file', metavar="DIRNAME",
dest='nonsyn', required=True, help='Required: Input OMI file with
nonsynonymous variants.')
parser.add_argument('-s', '--outseq_dir', metavar="DIRNAME",
dest='seqdir', required=True, help='Required: Name of output directory to
store aa sequence.')
parser.add_argument('-v', '--outvar_dir', metavar="DIRNAME",
dest='vardir', required=True, help='Required: Name of output directory to
store aa variations.')
parser.add_argument('-r', '--ref_sequence', metavar="ref_build",
dest='ref_seq', required=True, help='Required: Reference sequence file
used to translate aa,including path. Sequence should be split by
chromosome.')
parser.add_argument('-f', '--ref_flat', metavar="ref_flat",
dest='ref_flat', required=True, help='Required: Reference genomic field
used to identify gene region,including path. File should be split by
chromosome.')
args = parser.parse_args()
nonsynpath = args.nonsyn
aaseqpath = args.seqdir
aavarpath = args.vardir
build = args.ref_build
flat = args.ref_flat
nonsyn=pd.read_csv(nonsynpath)
seqname=[]
result=annotation(nonsyn,build,flat)
for j in range(len(result)):
nonsynidx=get_same_element_index(result[j][5],'Non-synonymous')
for n in range(len(nonsynidx)):
varfile=open(aavarpath+result[j][3][nonsynidx[n]]+".var", "a")
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varfile.write(nonsyn['AAchange'][j][nonsynidx[n]])
varfile.close()
if result[j][3][nonsynidx[n]] not in seqname:
seqname.append(result[j][3][nonsynidx[n]])
if result[j][2][nonsynidx[n]]=='-':
geneseq=result[j][6][n].upper().translate(trantab)
else:
geneseq=result[j][6][n].upper()
aaseq=''
for i in range(0,len(geneseq),3):
if len(geneseq)>=i+3 and AADict[geneseq[i:i+3]]!='*':
aaseq=aaseq+AADict[geneseq[i:i+3]]
else:
break
aaseq=re.sub("(.{60})","\\1\n",aaseq)
output=open(aaseqpath+result[j][3][nonsynidx[n]]+".fasta",
"w")
output.write("> sp|" + result[j][3][nonsynidx[n]] + "\n")
output.write(aaseq)
output.close()
output=open(aavarpath+"name.txt",'w')
for ele in seqname:
output.write(ele +"\n")
output.close()
#### modify the last character of sequence to make the stop codon as *
for i in range(len(seqname)):
var=pd.read_csv(aavarpath+seqname[i]+".var",header=None)
f=open(aaseqpath+seqname[i]+".fasta",'r')
sequence=f.readlines()
f.close()
if sequence[-1][-1]=="+":
sequence[-1]=sequence[-1][0:-1]+'*'
elif sequence[-1][-1]=="*":
continue
else:
sequence[-1]=sequence[-1]+'*'
for k in range(var.shape[0]):
loc=int(var.iloc[k,0][1:-1])
if sequence[loc-1]==var.iloc[k,0][0]:
continue
elif sequence[loc-2]==var.iloc[k,0][0]:
var.iloc[k,0]=var.iloc[k,0][0]+str(loc-1)+var.iloc[k,0][1]
elif sequence[loc]==var.iloc[k,0][0]:
var.iloc[k,0]=var.iloc[k,0][0]+str(loc+1)+var.iloc[k,0][1]
else:
print(seqname[i])
var.to_csv(aavarpath+seqname[i]+".var",index=False,header=False)
sequence=re.sub("(.{60})","\\1\n",sequence)
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fw=open(aaseqpath+seqname[i]+".fasta",'w')
fw.write("> sp|" + seqname[i] + "\n")
fw.write(sequence)
fw.close()
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D Pathogenic scores calculation
import pandas as pd
from collections import Counter
import math
import argparse
def get_same_element_index(ob_list, word):
return [i for (i, v) in enumerate(ob_list) if v == word]
def collect_gene(var_df):
singlegene=[]
provean_min=[]
fat_combine=[]
for i in range(var_df.shape[0]):
word=var_df['genename'][i].replace('\'', '').replace('[',
'').replace(']', '').replace(' ', '').split(',')
anno=var_df['where'][i].replace('\'', '').replace('[',
'').replace(']', '').replace(' ', '').split(',')
anno=list(filter(lambda x:x!='"Nottranslated' and
x!='Nottranslated',anno))
idx=get_same_element_index(anno,'CDS')
word1=[]
for ele in idx:
word1.append(word[ele])
singlegene.append(Counter(word1).most_common(1)[0][0])
provean=var_df['provean score'][i].split(",")
provean=list(map(lambda x:float(x),provean))
provean_min.append(min(provean))
if str(var_df['Coding Score'][4])=='nan':
fat_combine.append(float(var_df['Non-Coding Score'][i]))
else:
fat_combine.append(float(var_df['Coding Score'][i]))
var_df.insert(var_df.shape[1],'single gene',singlegene)
var_df.insert(var_df.shape[1],'provean min',provean_min)
var_df.insert(var_df.shape[1],'fat_combine',fat_combine)
var_df.insert(var_df.shape[1],'provean rank',var_df['provean
min'].rank())
var_df.insert(var_df.shape[1],'fathmm
rank',var_df['fat_combine'].rank(ascending=False))
var_df['rank sum']=var_df['fathmm rank']+var_df['provean rank']
var_df['rank-score']=1-var_df['rank sum']/(2*var_df.shape[0])
var_df=var_df.sort_values('rank sum',axis=0)
return var_df
def select_cds(curr):
maxium=0
for i in range(curr.shape[0]):
ex=0
m=0
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while ex != (len(curr.iloc[i,10])):
if curr.iloc[i,6] > curr.iloc[i,10][ex]:
ex+=1
elif curr.iloc[i,6] > curr.iloc[i,9][ex] and curr.iloc[i,6] <
curr.iloc[i,10][ex]:
m = (curr.iloc[i,10][ex] - curr.iloc[i,6])+m
ex+=1
else:
m = (curr.iloc[i,10][ex]-curr.iloc[i,9][ex])+m
ex+=1
if m> maxium:
maxium=m
return m
def pathogenic_score(var_df,gtf,out):
gene_counts=var_df['single gene'].value_counts()
patho_gene=gene_counts.reset_index()
patho_gene.rename(columns={'index':'genename','single gene':'distinct
pathogenic nsGSV'},inplace=True)
cds_length=[]
for i in range(patho_gene.shape[0]):
curr=gtf[gtf[0]==patho_gene.iloc[i,0]]
cds_length.append(select_cds(curr))
patho_gene.insert(patho_gene.shape[1],'CDS length',cds_length)
plg=[]
ptg=[]
for i in range(patho_gene.shape[0]):
curr=var_df[var_df['single gene']==patho_gene.iloc[i,0]]
plg.append(sum((curr['SubT1N0']-curr['SubT0N1'])*curr['rankscore'])/math.log(patho_gene.iloc[i,2]))
#curr=curr[(curr['SubT1N0']+curr['SubT1N1']>0) &
(curr['SubT0N1']+curr['SubT1N1']==0)]
ptg.append(sum((curr['SubT1N0']-curr['SubT0N1'])*curr['rankscore']))
patho_gene.insert(patho_gene.shape[1],'Pt(g)',ptg)
patho_gene.insert(patho_gene.shape[1],'Pl(g)',plg)
patho_gene.insert(patho_gene.shape[1],'Pt(g)
rank',patho_gene['Pt(g)'].rank(ascending=False))
patho_gene.insert(patho_gene.shape[1],'Pl(g)
rank',patho_gene['Pl(g)'].rank(ascending=False))
patho_gene.to_csv(out,index=False)
if __name__=='__main__':
parser = argparse.ArgumentParser(description='count subjects for each
variant')
parser.add_argument('-t', '--input_dir', metavar="nsGSV",
dest='nonsyn', required=True, help='Required: nsGSV files.')
parser.add_argument('-f', '--ref_flat', metavar="REFFLAT",
dest='ref_flat', required=True, help='Required: Reference genomic field
file.')
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parser.add_argument('-o', '--out_dir', metavar="DIRNAME",
dest='outfile', required=True, help='Required: Path and name of output
file.')
args = parser.parse_args()
var_df=pd.read_csv(args.nonsyn)
gtf = pd.read_table(args.ref_flat)
outdir = args.outdir
var_df=collect_gene(var_df)
pathogenic_score(var_df,gtf,outdir)
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